CLINICAL STUDY PROTOCOL
Study Title: A Phase 1 Study  to Evaluate OATP Transporter- Mediated 
Drug -Drug Interactions Between Filgotinib and Statins as Probe 
Drugs in Health y Participants
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
USA
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:115510
Not Applicable
Not Available
Indication: Rheumatoid Arthritis 
Protocol ID: GS-US-417-5937
Contact Information: The medical monitor name and contact information will be 
provided 
on the Key  Study  Team Contact List .
Protocol Version/Date: Original: 25Septemeber 2020
This study  will be conducted under U nited States Food andDrug Administration investigational 
new drug ( IND)regulations (21 
Code of Federal Regulations Part 312).
CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your st aff, and an applicable 
institutional review board or i ndependent ethics committee. The information is only  to be used 
by you in connection with authorized clinical studies of the investigational drug described in 
the protocol. You will not disclose any  of the information to others without written 
authorization from Gilead Sciences, Inc., except to the extent necessary  to obtain informed 
consent from those persons to whom the drug may be administered.
(r) GILEAU 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 2 25 Septemeber 2020TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABL ES........................................................................................................................................ 5
LIST OF IN-T EXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.1.1. Filgotinib General Information ............................................................................................ 16
1.1.2. Preclinical Pharmacology, Pharmacokinetics, and Toxicology ............................................ 17
1.1.3. Additional Clinical Studies of Filgotinib ............................................................................. 17
1.1.4. Atorvastatin .......................................................................................................................... 17
1.1.5. Pravastatin ............................................................................................................................ 18
1.1.6. Rosuvas tatin ......................................................................................................................... 18
1.2. Rationale for This Study ........................................................................................................................ 19
1.3. Rationale for the Dose Selection ............................................................................................................ 20
1.4. Risk/Benefit Assessment for the Study .................................................................................................. 21
1.5. Com pliance ............................................................................................................................................ 21
2. OBJECTIVES ..................................................................................................................................................... 22
3. STUDY DESIGN ................................................................................................................................................ 23
3.1. Study Design .......................................................................................................................................... 23
3.2. Study Drug Administration .................................................................................................................... 24
3.3. Duration of Dosing ................................................................................................................................. 24
3.4. Clini c Confinement ................................................................................................................................ 24
3.5. Pharm acokinetic Assessments ................................................................................................................ 24
3.5.1. Plasma Pharmacokinetic Collection ..................................................................................... 25
3.5.2. Genomic Sample Collection ................................................................................................. 25
3.6. Safety Assessments ................................................................................................................................ 25
3.7. End of Study ........................................................................................................................................... 25
3.8. Discontinuation Criteria ......................................................................................................................... 25
3.9. Source Data ............................................................................................................................................ 26
3.9.1. Discontinuation .................................................................................................................... 26
4. PARTICIPANT POPULATI ON......................................................................................................................... 27
4.1. Number of Participants and Participant Selection .................................................................................. 27
4.1.1. Participant Replacement ....................................................................................................... 27
4.2. Inclusion Criteria .................................................................................................................................... 27
4.3. Exclusion Criteria ................................................................................................................................... 28
5. STUDY D RUGS ................................................................................................................................................. 30
5.1. Randomization, Blinding, and Treatment Codes Access ....................................................................... 30
5.1.1. Randomization ..................................................................................................................... 30
5.1.2. Blinding ................................................................................................................................ 30
5.2. Description and Handling of Filgotinib .................................................................................................. 30
5.2.1. Form ulation .......................................................................................................................... 30
5.2.2. Packaging and Labeling ....................................................................................................... 30
5.2.3. Storage and Handling ........................................................................................................... 31
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 3 25 Septemeber 20205.3. Description and Handling of Commercially Available Drugs ............................................................... 31
5.4. Dosage and Administration of Study Drug ............................................................................................ 31
5.5. Fasting and Meals .................................................................................................................................. 32
5.6. Dispensing, Accountability, and Disposal or Return of Study Drug ...................................................... 32
5.7. Concomitant Medications and Other Protocol Restrictions ................................................................... 33
5.7.1. Concomitant Medications ..................................................................................................... 33
5.7.2. Other Protocol Restrictions .................................................................................................. 33
6. STUDY ASSESSMENTS ................................................................................................................................... 35
6.1. Participant Enrollment and Treatment Assignment ................................................................................ 35
6.2. Pretreatment Assessments ...................................................................................................................... 41
6.2.1. Screening Assessments ......................................................................................................... 41
6.2.2. Admission Assessments ....................................................................................................... 41
6.3. Check -in Assessments ............................................................................................................................ 42
6.4. Treatment Assessments .......................................................................................................................... 42
6.5. Pharm acokinetic Assessments ................................................................................................................ 42
6.5.1. Plasma PK Collection ........................................................................................................... 42
6.6. Safety Assessments ................................................................................................................................ 43
6.6.1. Electrocardiogram Assessment ............................................................................................ 43
6.6.2. Physical Examination ........................................................................................................... 43
6.6.3. Vital Signs ............................................................................................................................ 44
6.6.4. Body  Mass Index .................................................................................................................. 44
6.6.5. Clinical Laboratory Tests/Assessments ................................................................................ 44
6.6.6. Creatinine Clearance ............................................................................................................ 45
6.6.7. Adverse Events/Concomitant Medications/Protocol Restrictions ........................................ 45
6.7. Posttreatment Assessments .................................................................................................................... 45
6.8. Assessments for Early Discontinuation from Study ............................................................................... 45
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 46
7.1. Definitions of Adverse Events and Serious Adverse Events .................................................................. 46
7.1.1. Adverse Events ..................................................................................................................... 46
7.1.2. Serious Adverse Events ........................................................................................................ 46
7.1.3. Study Drugs and Gilead Concomitant Therapy Special Situations Reports ......................... 47
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 48
7.2.1. Assessment of Causality for Stu dy Drugs and Procedures ................................................... 48
7.2.2. Assessment of Severity ........................................................................................................ 48
7.3. Investigator Reporting Requirements and Instructions .......................................................................... 49
7.3.1. Requirements fo r Collection Prior to Study Drug Initiation ................................................. 49
7.3.2. Adverse Events ..................................................................................................................... 49
7.3.3. Serio us Adverse Events ........................................................................................................ 49
7.3.4. Study Drug Special Situations Reports ................................................................................ 49
7.3.5. Concomitant Therapy Reports .............................................................................................. 49
7.4. Reporting Process for Serious Adverse Events and Special Situation Reports ...................................... 50
7.4.1. Serious Adverse Event Reporting Process ........................................................................... 50
7.4.2. Special Situations Reporting Process ................................................................................... 51
7.5. Gilead Reporting Requirements ............................................................................................................. 52
7.6. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 53
7.7. Toxicity Management ............................................................................................................................ 53
7.7.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 53
7.7.2. Grades 3 Laboratory Abnormality or Clinical Event ........................................................... 53
7.7.3. Grades 4 Laboratory Abnormality or Clinical Event ........................................................... 54
CCI
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 4 25 Septemeber 20208. STATISTICAL CONSIDER ATIONS ................................................................................................................ 55
8.1. Analysis Objectives and Endpoints ........................................................................................................ 55
8.1.1. Analysis Objectives .............................................................................................................. 55
8.1.2. Primary Endpoint ................................................................................................................. 55
8.1.3. Secondary Endpoint ............................................................................................................. 55
8.2. Planned Analyses ................................................................................................................................... 55
8.2.1. Final Analysis ....................................................................................................................... 55
8.3. Analysis Conventions ............................................................................................................................. 56
8.3.1. Analysis Sets ........................................................................................................................ 56
8.3.2. Data Handling Conventions ................................................................................................. 56
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 56
8.5. Safety Analysis ....................................................................................................................................... 57
8.5.1. Extent of Exposure ............................................................................................................... 57
8.5.2. Adverse Events ..................................................................................................................... 57
8.5.3. Laboratory Evaluations ........................................................................................................ 57
8.5.4. Other Safety Evaluations ...................................................................................................... 57
8.6. Pharm acokinetic Analysis ...................................................................................................................... 57
8.7. Sample Size ............................................................................................................................................ 58
9. RESPONSIBILITIES .......................................................................................................................................... 59
9.1. Investigator Responsibilities .................................................................................................................. 59
9.1.1. Good Clinical Practice .......................................................................................................... 59
9.1.2. Financial Disclosure ............................................................................................................. 59
9.1.3. Institutional Review Board Review and Approval ............................................................... 59
9.1.4. Informed Consent ................................................................................................................. 59
9.1.5. Study Files and Retention of Records .................................................................................. 60
9.1.6. Case Report Forms ............................................................................................................... 61
9.1.7. Investigator Inspections ........................................................................................................ 62
9.1.8. Protocol Compliance ............................................................................................................ 62
9.2. Sponsor Responsibilities ........................................................................................................................ 62
9.2.1. Protocol Modifications ......................................................................................................... 62
9.2.2. Study Report and Publications ............................................................................................. 62
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 63
9.3.1. Payment Reporting ............................................................................................................... 63
9.3.2. Access to Information for Monitoring .................................................................................. 63
9.3.3. Access to Information for Auditing or Inspections .............................................................. 63
9.3.4. Study Discontinuation .......................................................................................................... 63
10. REFERENCES ................................................................................................................................................... 64
11. APPENDICES .................................................................................................................................................... 65
Appendix 1. Investigator Signature Page .................................................................................................... 66
Appendix 2. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 67
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 70
Appendix 4. Common Terminology Criterial for Adverse Events (CTCAE) Grading Scale v5.0 ............. 71
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 5 25 Septemeber 2020LIST OF IN -TEXT TABL ES
Table 6-1. Schedule of Assessments (Sequence AB) .............................................................................. 36
Table 6-2. Schedule of Assessments (Sequence BA) .............................................................................. 38
LIST OF IN -TEXT FIGU RES
Figure 3-1. Study Schema –Sequence AB ............................................................................................... 23
Figure 3-2. Study Schema –Sequence BA ............................................................................................... 24
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 6 25 Septemeber 2020PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
USA
Study Title: A Phase 1 Study  to Evaluate OATP Transporter- Mediated 
Drug -Drug Interactions Between Filgotinib and Statins as Probe 
Drugs in Health y Participants
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:115510
Not Applicable
Not Available
Study Centers 
Planned:Single Phase 1 center in the United States (US)
Objectives: The primary  objective of this study  is as follows:
To evaluate the effect of filgotinib on a mi xed organic anion 
transporting pol ypeptide/cytochrome P450 3A (OATP/CYP3A), 
OATP/breast cancer resistance protein (BCRP), and OATP 
substrates using phenotypic probes
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  of multiple filgotinib doses 
administered alone or in combination with probe drugs
Study Design: Phase 1, randomized, two -way cross-over, open- label, single and 
multiple dose, single center study
Number of 
Participants
Planned:30 participants (for 26 evaluable)
Target Population: Health y nonpregnant, nonlactating female and surgically sterile male 
participants, aged 18 -55, inclusive
Duration of 
Dosing:13 day s
Study  Duration: Up to 27 day s(not including screening window) for Sequence AB
Up to 30 days(not including screening window) for Sequence BA
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 7 25 Septemeber 2020Diagnosis and 
Main Eligibility  
Criteria:Eligible participants will be surgicall y sterile male and nonpregnant, 
nonlactating female participants, with body  mass index (BMI) of 
≥19 and ≤ 30 kg/m2, normal 12- lead electrocardiogram (ECG), 
normal renal function, and no significant medical history . 
Participants will also be in good general health as determined b y the 
investigator at the screening evaluation performed no more than 
28days prior to the scheduled first dose.
Study  Procedures/
Frequency :Following completion of screening and admission assessments 
(Day 1), eligible participants will be randomized the evening of 
Day 1 to receive 1 of 2 treatment sequences starting on Day 1:
The study  treatments are as follows:
OATP/CYP3A substrate: Atorvastatin (ATV) 40 mg
OATP substrate: Pravastatin (PRA) 40 mg
OATP/BCRP substrate: Rosuvastatin (ROS) 10 mg
Pravastatin/Rosuvastatin (PRA/ROS) will be coadministered as a 
probe cocktail
Treatment A: Singl e dose of ATV 40 mg, followed by  a washout 
period of one day  or a single dose of the PRA 40 mg /ROS 10 mg
cocktail 
Treatment B: Filgotinib 200 mg administered once dail
yfor 11 
days, with a single dose of ATV 40 mg administered on the sixthday 
followed b ya single dose of PRA 40 mg /ROS 10 mg cocktail 
administered on the eighth day
Sequence Days
ABPeriod 1 Period 2
1 2 3 4-67-
11 12 13 1415-
17
ATV WOPRA 
+ 
ROSWO FILFIL +
ATVFILFIL 
+ 
PRA 
+ 
ROSFIL
BAPeriod 1 Period 2
1-5 6 7 89-
1112-
17
18 19 20
FILFIL + 
ATVFILFIL 
+ 
PRA 
+ 
ROSFIL WO ATV WOPRA 
+ 
ROS
FIL  filgotinib; ATV  atorvastatin; PRA  pravastatin; ROS  rosuvastatin ; 
WO washout
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 8 25 Septemeber 2020Study Visits and Confinement
Following screening and admission assessments, eligible participants 
will be confined to the study  center beginning Day 1 until the 
completion of assessments on Day  17 (Sequence AB) or Day 23 
(Sequence BA). All participants will be contacted by  
telephone 7(±2) day s after last dose for follow up (ie, on Day  24 
[±2] for S equence AB or Day  27 [± 2] for Sequence BA).
Study Drug Administration
All study  treatments will be administered at approximately  the same 
time each day  with 240 mL  of water following an overnight fast 
(nofood or drinks except water) for at least 10 hours. On 
non-intensive Pharmacokinetic ( PK)days, participants will continue 
to fast for 2 hours 
after dosing postdose relative to study  drug 
dosing.
On the day s of intensive PK sampling, study  treatments will be 
administered in the morning following an o vernight fast (no food or 
drinks except water for at least 10 hours). Participants will continue 
to fast until after collection of the 4 -hour PK sample, relative to 
study  drug dosing. Additionally , participants will be restricted from 
water consumption 1 h our before and until 2 hours after dosing, 
except for the 240 mL given with the study  treatment. After 
collection of the 4 -hour PK sample, participants will be provided 
with a standardized meal.
Pharmacokinetic Assessments
Intensive plasma PK sampling will occur relative to dosing of stud y 
drug at the following time points for each study  day as specified 
below:
Sequence AB:
Days 1 and 12: 0 (pre -dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 24, 36, and 48 hours postdose
Days 3 and 14: 0 (pr e-dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 
12, 16, 24, 48, and 72 hours postdose
Sequence BA: 
Days 6 and 18: 0 (pre -dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 24, 36, and 48 hours postdose
Days 8 and 20: 0 (pre -dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 
12, 16, 24, 48, and 72 hours postdose
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 9 25 Septemeber 2020Plasma concentrations of ATV , PRA , and ROS will be determined 
and PK evaluated. Plasma concentrations of filgotinib and its 
metabolite (GS -829845) may  be anal yzed. Plasma concentrations of 
metabolites of probe drugs or filgotinib may be analy zed, if 
applicable.
Safety Assessments
Assessment of adverse events (AEs) and concomitant medications 
will continue thr oughout the study . All clinical and clinically  
significant laboratory  toxicities will be managed according to 
uniform guidelines detailed in protocol Appendix 4 .
The schedules of assessments are as follows:
Sequence AB
Complete physical exam: screening, admission (Day 1), Day  9, 17,
and at the earl y termination (ET) visit, if applicable. 
Symptom -driven physical exam: Daily  during confinement as needed 
based on reported signs and sy mptoms
Vital signs (blood pressure, heart rate, respiration rate, and body 
temperature): Screening, Adm
ission (Day  1), Day s 1, 3, 6, 7, 10, 
12, 14, 15, 17, and at the ET visit, if applicable
Height: Screening
Weight: Screening, Admission (Day 1), Day s 7, 14, 17, and at the 
ET visit, if applicable
12-lead ECG: Screening 
Hepatitis B virus (HBV) , hepatitis C virus (HCV) , human 
immunodeficiency virus type 1 testing (HIV -1): Screening
Follicle Stimulating Hormone (FSH): Screening
Urine drug and alcohol assessments: Screening and Admission 
(Day 1)
Thyroid- stimulating hormone (TSH): Screening
Serum pregnancy t est (female of childbearing potential only): 
Screening, Admission (Day 1), (Day 17), and at the ET visit, if 
applicable
Urine pregnancy test :Admission (Day  1), Day  7 
Clinical laboratory tests (hematology, chemistry, creatine 
phosphokinase 
[CPK ],and urinalysi): Screening, Admission 
(Day 1), Day s 1, 3, 6, 7, 12, 13, 14, 15, 17, and at the ET visit, if 
applicable
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 10 25 Septemeber 2020Calculated Creatinine Clearance (CL cr): Screening, Admission 
(Day 1), Day s 7, 14, 17, and at the ET visit, if applicable
Sequence BA
Complete physical exam: Screening, Admission (Day  1), Day s 9,
23, and at the ET visit, if applicable 
Symptom -driven physical exam: Daily  during confinement as needed 
based on reported signs and sy mptoms
Vital signs (blood pressure, heart rate, respiration rate, and body 
temperature): Screening, Admission (Day  1), Day s 1, 3, 6, 7, 8, 9, 
11, 18, 20, 23 and at the ET visit, if applicable
Height: Screening
Weight: Screening, Admission (Day  1), Day s 7, 11, 18, 23, and at 
the ET visit, if applicable
12-lead ECG : Screening 
Hepatitis B virus (HBV) , hepatitis C virus (HCV) , human 
immunodeficiency virus type 1 testing (HIV -1): Screening
Follicle Stimulating Hormone (FSH): Screening
Urine drug and alcohol assessments: Screening and Admission 
(Day 1)
Thyroid
-stimulating hormone (TSH): Screening
Serum pregnancy test (female of childbearing potential only): 
Screening, Admission (Day  1), Day s 7and 20 and at the ET visit, if 
applicable
Urine pregnancy test : Admission (Day  1), Day  7 
Clinical laboratory tests (hematology, chemistry, CPK, and 
urinalysis): Screening, Admission (Day  1), Day s 1, 5, 6, 7, 8, 9, 11, 
18, 20, 23 and at the ET visit, if applicable
Calculated Creatinine Clearance (CL cr): Screening, Admission 
(Day 1), Day s 7, 11, 18, 
and 23,and a t the ET visit, if applicable
All Sequences
Coronavirus Disease 2019 (COVID -19) Real -Time Reverse 
Transcriptase -Polymerase Chain Reaction (RT -PCR) Test: 
RT-PCR 
testing will be conducted and reviewed per site specific policy  at 
Screening, Admission, and as needed during the study . Alternatively , 
a comparable test may  be used after consultation with the Sponsor.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 11 25 Septemeber 2020Genomic Sample Collection
A single blood sample for genomic testing and genoty ping to 
identify  polymorphisms of drug transporters (eg, OATP1B1) will be 
obtained for all participants and may  be anal yzed, as applicable. This 
sample should be collected on Day  1, but may  be collected at an y 
time during the stud y, if necessary .
Test Product, Dose, 
and Mode of 
Administration:Treatment B: Filgotinib 200 mg administered once dail
ywith a 
single dose of ATV 40 mg or a single dose of PRA 40 mg /ROS
10mgcocktail. All agents should be administered in the morning 
under fasted conditions.
Reference Therapy, 
Dose, and Mode of 
Administration:Treatment A: Single dose of ATV 40 mg or a single dose of the 
PRA 40 mg /ROS 10mgcocktail administered in the morning under 
fasted conditions.
Criteria for 
Evaluation:
Safety : Safety  will be assessed during the study  through the documentation 
of AEs, and 
by clinical laboratory  tests, phy sical examinations, vital 
signs, and 12 -lead safet y ECGs at various time points during the 
study .
Efficacy : Not applicable
Pharmacokinetics: The following plasma PK parameters will be calculated for ATV , 
PRA , and ROS , as applicable: AUC last, AUC inf, %AUC exp, Cmax, Clast, 
Tmax, Tlast, t1/2, CL/F, λz, and V z/F.
PK parameters for other anal ytes may  be determined.
Statistical Methods: Pharmacokinetics :
Plasma concentrations and PK parameters will be listed and 
summarized using descriptive statistics by  treatment. 
An anal ysis of variance (ANOVA) using a mixed -effects model with 
treatment, and sequence as fixed effects and participant as a random 
effect w ill be fitted to the natural logarithmic transformation of PK 
parameters (AUC last, AUC inf, and C max) for each analy te. Two -sided 
90% CI s will be calculated for the ratios of geometric least- squares 
means (GLSMs) of primary  PK parameters between test (Treat ment 
B) versus reference (Treatment A) treatments. Lack of PK 
interaction between the test and reference treatments will be 
concluded if the 90% CIs for the GLSM ratios are contained within 
the 0.70 and 1.43 range for ATV, PRA, and ROS AUC and C max. 
Additi onal analy ses may  be performed if useful and appropriate. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 12 25 Septemeber 2020Safety : 
The AE data will be listed by  participant . Treatment -emergent AEs, 
serious adverse events (SAEs), and AEs leading to permanent stud y 
drug discontinuation will be summarized by  treatment, system organ 
class, and preferred term using the current version of the Medical 
Dictionary  for Regulatory  Activities (MedDRA).
Listings of individual participant laboratory  results will be provided. 
Laboratory  results and change from predose values for se lected lab 
tests will be summarized by  treatment sequence at scheduled visits. 
The incidence of treatment -emergent laboratory  abnormalities will 
be summarized by  treatment.
Vital signs and ECG data will be summarized by  treatment/treatment 
sequence.
Sample Size:
With 26 evaluable participants the estimated two -sided 90% CI of 
the GL SM ratio of test v ersus reference treatments, with regards to 
AUC inf, AUC last,and C max, will be within [70%, 143%] with ≥ 85% 
probability , if the true GLSM ratio is 1.0. This is assuming a 
standard deviation (SD) of differences of no more than 0.569 on a 
natural logarithm scale, supported b y PK data from Study  
GS-US-402- 2102. With 4 participants for overage, a total sample 
size of 30 participants will be required.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice 
(GCP) including archiving of essential documents.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 13 25 Septemeber 2020GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
%AUC exp percentage of AUC extrapolated betw een AUC last and AUC inf
AE adverse event
AE adverse events 
eCRF electronic case report form
ALT alanine aminotransferase
ANOVA analysis of variance
AS ankylosing spondylitis
AST aspartate aminotransferase
ATV atorvastatin
AUC area under the concentration versus time curve
AUC inf area under the concentration versus time curve extrapolated to infinite time, calculated 
as AUC last + (C last/z)
AUC last area under the concentration versus time curve from time zero to the last quantifiable 
concentration
BCRP breast cancer resistance pr otein
BMI body mass index
CD Crohn’s Disease 
CI confidence interval
CK creatine kinase
Clast last observed quantifiable concentration of the drug
CL cr creatinine clearance
Cmax maximum observed concentration of drug
COVID -19 RT -PCR a real -time reverse transcription polymerase chain reaction (rTT -PCR) test for the 
qualitative detection of nucleic acid from SARS -CoV -2
CPK creatine phosphokinase
CTCAE Common Terminology Criteria for Adverse Events
DDI drug-drug interaction
DNA deoxyribonucleic acid
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
EMA European Medicines Agency
ET early termination
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
Gilead Gilead Sciences
GLPS Global Patient Safety
GLSM geometric least -squares mean
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 14 25 Septemeber 2020HBV hepatitis B virus
HCV hepatitis C virus
HIV-1 human immunodeficiency virus type 1
HMG- CoA 3-hydroxy -3-methylglutaryl -coenzyme A
IB investigator’s brochure
IBD inflammatory bowel disease
ICF informed consent form
ICH International Council for Harmonisation (of Technical Requirements for 
Pharm aceuticals for Human Use) 
IC50 half maximal inhibitory concentration
IND investigational new drug
IRB institutional review board
JAK Janus kinase
z terminal elimination rate constant, estimated by linear regression of the terminal 
elimination phase of the log concentration of drug versus time curve of the drug
LDL low-density lipoprotein
LLOQ lower limit of quantitation
Macrogo l/PEG 3350 based oral osmotic laxative promotes the retention of water in the bowel
MedDRA Medical Dictionary for Regulatory Activities
OATP organic anion transporting polypeptide
OATP/CYP3A organic anion transporting polypeptide/cytochrome P450 3A
PCR polymerase chain reaction
PK pharmacokinetic(s)
PRA Pravastatin
PRA/ROS Pravastatin/Rosuvastatin
PsA psoriatic arthritis
PT preferred term
QT syndrome a disorder of the heart’s electrocial activity
RA rheumatoid arthritis
ROS Rosuvastatin
SAE serious adverse event
SD standard deviation
SDV source data verification
SOC system organ class
SOP standard operating procedure
SSRs Special situation reports
STAT signal transducer and activator of transcription
SUSAR suspected unexpected serious adverse reaction
t1/2 estimate of the terminal elimination half -life of the drug, calculated by dividing the 
natural log of 2 by the terminal elimination rate constant ( z)
TEAE treatment -emergent adverse event
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 15 25 Septemeber 2020TSH thyroid -stimulating hormone
TYKs tyrosine kinases
UC ulcerative colitis
US United States
Vz/F apparent volume of distribution of the drug
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 16 25 Septemeber 20201. INTRODUCTION
1.1. Background
Over the last decade changes in rheumatoid arthritis (RA) treatment strategies, accompanied b y 
advances in drug development and the addition of targeted biological therapies, have greatl y 
improved the outcomes for patients with RA. Despite these developmen ts, therapeutic challenges 
remain. The current conventional and biological disease -modify ing anti- rheumatic drugs 
(DMARDs) may  be ineffective or produce onl y partial responses in some patients and are 
associated with significant safety and tolerability concerns. There is an unmet medical need for 
simple, orally  administered therapies with novel mechanisms of action that can effectivel y 
improve the disease course while being safe and well tolerat ed. 
Janus kinases (JAKs) are intracellular cy toplasmic ty rosine kinases (TYKs) that transduce 
cytokine signaling from membrane receptors to the nucleus of cells. JAK/ signal transducer and 
activator of transcription (STAT )signaling pathway s are evolutiona rily conserved and 
ubiquitous in humans and animals and are activated by  a variety  of cy tokines, growth factors, 
and other chemical messengers.
Filgotinib is a potent JAK inhibitor that is highly  selective for JAK1. The main metabolite of 
filgotinib, GS -829845, is pharmacologically  active and is also a selective inhibitor of JAK1. I t is 
expected that targeted inhibition of JAK1 will retain the clinical efficacy , while improving upon 
the safet y profile of the less selective JAK family inhibitors. To date, JA K inhibitors approved 
for the treatment of RA include tofacitinib, baricitinib
,and upadacitinib. Filgotinib is currentl y in 
development for the treatment of multiple inflammatory  conditions including RA, psoriatic 
arthritis (PsA), ank ylosing spond ylitis (AS), ulcerative colitis (UC), Crohn’s disease (CD) ,and 
uveitis. 
1.1.1. Filgotinib General Information
Filgotinib (GS -6034, formerly  GLPG0634) is a n orally  administered potent and selective 
inhibitor of JAK1. JAK inhibitors block the signaling of various cy tokin es, growth factors, and 
hormones, including the pro -inflammatory  cytokine IL -6. Four different types of JAKs are 
known, JAK1, JAK2, JAK3, and TYK2 which co -interact with different sets of membrane 
receptors. Inhibition of JAKs is a promising therapeutic op tion for a range of inflammatory  
conditions including RA, UC, and CD. The compound has shown good preliminary  efficacy  in 
participants with PsA {Mease 2018 }, AS{van der Heijde 2018} and CD in Phase 2 studies 
(filgotinib Investigator ’sBrochure [IB]Edition 15, dated 03 September 2020 ). In Phase 3 RA 
studies , filgotinib was generall y well tolerated for the duration of the studies (24 weeks in 
GS-US-417- 0302 and 52 weeks in GS -US- 417-0301 and GS -US- 417-0303) (filgotinib IB) . 
Filgotinib is currently  under assessment in ongoing Phase 3 PsA, UC, CD studies 
(clinicaltrials.gov). Additionally , filgotinib is currently  under review b y regulatory  agencies for 
the treatment of adults who are living with moderate- to-severe RA. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 17 25 Septemeber 2020For further information on f ilgotinib , refer to theIB, including information on the following :
Nonclinical pharmacokinetic ( PK)and in vitro m etabolism
Nonclinical pharmacology  and toxicology
Clinical experience
1.1.2. Preclinical Pharmacology , Pharmacokinetics ,and Toxicology
For detailed information on all supporting preclinical data for filgotinib, please refer to the IB.
1.1.3. Additional Clinical 
Studies of Filgotinib
An overview of clinical studies conducted with filgotinib is available in the IB.
As of 30 June 2020, 41 Phase 1, 2, and 3 clinical studies have been conducted/are ongoing in 
which 394 health y volunteers or special populations (15 subjects with renal impairment and 
10 subjects with hepatic impairment), 4126 subjects with RA, an estimated 1121 subjects with 
CD, an estimated 1334 subjects with UC, 94 subjects with AS, an estimated 178 subjects with 
PsA, and an estimated 111 subjects with other inflammatory  diseases have been dosed with 
filgotinib. Subjects in long -term extension (L TE) studies (Studies GL PG0634 -CL-205, 
GS-US-417- 0304, GS -US- 419-3896, a nd GLPG0634- CL-225) were not included in subject 
numbers in order to eliminate double-counting. Information About A torvastatin, Pravastatin ,
andR
osuvastatin
1.1.4. Atorvastatin
Atorvastatin (ATV) is a sy nthetic lipid -lowering agent that works via inhibition of 
3-hydroxy - 3 -methy lglutary l-coenz yme A (HMG- CoA) reductase. This enzyme catal yzes the 
conversion of HMG -CoA to mevalonate, an early  and rate -limiting step in cholesterol 
biosy nthesis. Atorvastatin 40 mg is representative of the middle of the recommended ATV dose 
range used in clinical practice (10 mg to 80 mg). Drug interactions resulting in significant 
changes in ATV exposure generally  involve inhibition of cy tochrome P450 (CYP ) 3A4 
(eg,cyclosporine) (Elsby et al 2012) , and filgotinib has been show to not i nhibit CYP34A4 in 
vivo GL PG0634- CL-103; accordingl y, large increases in ATV exposure are not expected when 
administered with filgotinib, which does not inhibit CYP enzy mes. 
Atorvastatin, as well as some of its metabolites, are pharmacologicall y active in humans. The 
liver is the primary  site of action and the principal site of cholesterol s ynthesis and low -density  
lipoprotein ( LDL)clearance. Atorvastatin has 14% bioavailability  via oral administration and is 
rapidly  absorbed after oral administration in the fasted state ; maximum plasma concentrations 
occur within 1 to 2 hours. Food slows the rate of absorption. Hepatic CYP3A4 is the major 
metabolic pathway . Elimination is mostly  through the biliary  route, with 1
-2% also being 
excreted renally . Mean plasma elimination half -life of ATV in humans is approximately  
14hours, but the half -life of inhibitory  activity  for HMG -CoA reductase is 20 to 30 hours due to 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 18 25 Septemeber 2020the contribution of active metabolites. Atorvastatin 10 to 80 mg once daily  is the recommended 
dose range used in clinical practice to treat h yperlipidemia or to prevent cardiovascular disease.
Further information regarding ATV is available in the prescribing information .
1.1.5. Pravastatin
Pravastatin (PRA) is a HMG -CoA reductase inhibitor used in patients with elevated cholesterol 
and with a risk of cardiovascular disease. In this study , PRA 40 mg (1  40 mg tablet), will be 
administered as a single dose to healthy  participants to assess organic anion transporting 
polypeptide (OATP )activity  in the presence and absence of filgotinib. The sensitivity  of PRA as 
an in vivo probe for assessing OATP activity  at this dose has been previously  established 
{Giacomini 2010 }.
After oral administration, peak plasma PRA concentrations were observed 1 to 1.5 hours 
postdose. Based on urinary  recovery  of total radiolabeled drug, the average oral absorption of 
PRA is 34% and absolute bioavailability  is 17%. Food in the gastrointestinal tract reduces 
systemic bioavailability  of PRA. P ravastatin is not extensively  protein bound (50%). The major 
biotransformation pathway s of PRA are 1) isomerization to 6 -epi PRA and the 
3α-hydroxyisomer of PRA and 2) enz ymatic ring hy droxylation. Approximately  20% of a 
radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration 
of radiolabeled PRA to healthy  participant s, approximately  47% of total body  clearance was via 
renal excretion and 53% by  non- renal routes (eg, biliary  excretion and biotransformation). 
Follow ing single dose oral administration of 14C- PRA , the radioactive elimination t 1/2 for PRA is 
1.8 hours in humans. 
Pravastatin is indicated for hyperlipidemia and for cardiovascular disease 
prevention, the recommended starting dose is 40 mg once dail y, and t o use 80 mg dose onl y for 
patients not reaching LDL -Cholesterole goal with 40 mg. 
Further information regarding PRA is available in the prescribing information .
1.1.6. Rosuvastatin
Rosuvastatin (ROS), is a HMG-CoA reductase inhibitor used in patients with elevated 
cholesterol and with a risk of cardiovascular disease. In this study , ROS 10 mg (1  10 mg tablet) 
will be administered as a single dose to healthy  participants to collectively  assess 
OATP1B1/1B3
and breast cancer resistance protein (BCRP )activity  in the presence and absence 
of filgotinib {Chu 2018, Giacomini 2010 }.
The re lative contribution of OATP and BCRP in determining in vivo ROS disposition is not 
known. However, emerging data on the significance of SLCO1B1 pol ymorphisms and associated 
statin -induced my opathy  provides compelling evidence on the importance of OATP in R OS PK
{Elsby  2012 , Meyer zu Sc hwabedissen 2009 , Neuvonen 2010 , Pasanen 2007}. Collectively , use 
of both PRA and ROS as probes in this study  will allow for a better understanding and/or 
discrimination of the effects of filgotinib on OATP and BCRP. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 19 25 Septemeber 2020Rosuvastatin can be taken with or without food, any  time of the day , over a dose ran ge of 5 to 
40mg once dail y. Rosuvastatin peak plasma concentrations are reached in 3 to 5 hours after oral 
dosing, and administration with food does not affect the AUC of ROS. Rosuvastatin is not 
extensively  metabolized and the major metabolite, N -desmeth yl rosuvastatin, is formed 
principally  by CYP 2C9; this metabolite display s one -sixth to one -half of the 
HMG -CoA -reductase inhibitory  activit y of the parent. Overall, greater than 90% of active 
plasma HMG -CoA -reductase inhibitory  activity  is accounted for b y the parent compound. The 
elimination half -life of ROS is approximately  19 hours. Rosuvastatin clearance is not dependent 
on metabolism by  CYP 3A4 to a clinicall y significant extent. 
Further information regarding ROS is available in the package insert.
1.2. Rationale for 
This Study
The objective of this study  is to evaluate filgotinib as a perpetrator of drug -drug interactions
(DDIs) with OATPs. Filgotinib and its metabolite, GS -829845, are determined to be in vitro 
inhibitors of OATP1B1 and OATP1B3. Filgotinib inhibits OATP1B1 and OATP1B3 at a 
half-maximal inhibitory  concentration ( IC50)of 98 µM and > 285 µM, respectivel y. GS -829845 
inhibits OATP1B1 and OATP1B3 at an IC50of 260 µM and > 473 µM, respectivel y 
(AD-417- 2024). Based on in vitro data, filgotinib an d GS -829845 are unlikely  to have in vivo 
DDIs mediated b y OATP1B1 and OATP1B3. Data generated from this study will be used to 
further support 
the use of filgotinib with OATP substrates such as statins. This study  will 
evaluate the potential effect of filgo tinib and GS- 829845 on OATP1B1 and OATP1B3 
transporters using probe substrates of ATV (probe for CYP3A and OATP), ROS (probe for 
BCRP and OATP), and PRA (probe for OATP). The probe drugs selected for this study  are 
based on the recommendations from the International Transporter Consortium on “Membrane 
Transporters in Drug Development” and “Transporters in Drug Development: Advancing on the 
Critical Path”{Giacomini 2010 , Huang 2010 }.
The design of this study  is based on the results of a comprehensive panel of nonclinical studies, 
and in accordance with the Food and Drug Administration (FDA )guidance entitled “Drug 
Interaction Studie s Study  Design, Data Anal ysis, Implications for Dosing, and Labeling 
Recommendations” (Jan 2020) and the European Medicines Agency  (EMA )guidance entitled 
“Guideline on the Investigation of Drug Interactions” (June 2012).
Data from this DDI stud
y will inform the suitability of filgotinib co -administration with 
concomitant medications and the need for dose adjustment, as applicable.
Health y participant s will be selected for this study  to remove any  potential confounding effects 
of background medications an d other therapies, and to avoid the need to make multiple, 
short -term changes in treatment regimens in patients for the purpose of examining the PK of the 
different agents and their combinations. For safet y and adherence monitoring, all participants 
will b e confined within a Phase 1 unit for the duration of the study .
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 20 25 Septemeber 20201.3. Rationale for the Dose Selection
Filgotinib will be administered at 200 mg once daily  for 11 day s. The 200 mg once daily dose of 
filgotinib is the highest therapeutic dose under evaluation for multiple inflammatory  diseases 
including RA, UC, PsA, and AS. This dose has been selected based on efficacy , tolerability , and 
safet y data derived across Phase 1, Phase 2, and Phase 3 clinical studies. In Phase 2 and Phase 3 
studies in participants with RA, treatment with filgotinib was well tolerated and achieved a high 
level of efficacy  (ACR20/50/70) at a 200 mg daily dose. Exposure -efficacy  anal ysis based on 
data from all Phase 2 an d Phase 3 studies indicated an increase in efficacy  (ACR50/70) with 
increasing filgotinib exposure, with a plateau in response corresponding to filgotinib exposures 
at the 200 mg daily  dose. No trend in adverse events (AEs) or laboratory  abnormalities have
been observed in exposure- safety  anal ysis of filgotinib up to 300 mg administered as once dail y 
doses. Therefore, the 200 mg dose of filgotinib is selected as the clinicall y relevant dose for 
evaluation. Multiple doses of filgotinib at 200 mg once dail y is selected to achieve stead y state 
exposure of filgotinib and its metabolite, GS- 829845, in order to assess the potential impact of 
the highest clinically  relevant exposure of filgotinib (as an inhibitor) on the PK of the OATP 
transporter probes ( ATV , ROS ,and PRA ).
Atorvastatin 40 mg (1  40 mg tablet) will be administered as a single dose to healthy  
participants in a crossover design to assess OATP activity  in the presence and absence of 
filgotinib. Atorvastatin 40 mg is representative of the middle of th e recommended ATV dose 
range used in clinical practice (10 mg to 80 mg). Drug interactions resulting in significant 
changes in ATV exposure generally  involve inhibition of CYP3A4 (eg, cyclosporine) 
{Elsby 2012 }.Additionally , filgotinib is not expected to be a strong inhibitor of OATPs. 
Accordingl y, large increases in 
ATV exposure are not expected when administered with 
filgotinib, which does not inhibit CYP enzy mes.
Pravastatin 40 mg (1 40 mg tablet) will be administered as a single dose to healthy  participants 
in a crossover design to assess OATP activity  in the presence and absence of filgotinib. 
Pravastatin 40 mg is representative of the middle of the PRA dose range used in clinical practice 
(10 mg to 80 mg). The sensitivity  of PRA as an in vivo probe for assessing OATP activity  at this 
dose has been previousl y established 
{Giacomini 2010 }. 
Rosuvastatin 10 mg (1 10 mg tablet ) will be administered as a single dose to healthy  
participants in a crossover design to collectivel
y assess OATP1B1/1B3 and BCRP activity in the 
presence and absence of filgotinib {Chu 2018, Giacomini 2010 }. Rosuvastatin 10 mg is 
representative of the recommended dose range used in clinical practice (5 mg to 40 mg). 
Collectively , use of both PRA and ROS as probes in this study  will allow for a better 
understandin g and/or discrimination of the effects of filgotinib and its primary  metabolite on 
OATP and BCRP.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 21 25 Septemeber 2020Rosuvastatin and PRA will be administered as a cocktail of drug transport probe substrates. The 
use of this cocktail as a measure of OATP and BCRP activity  has been confirmed in a previous 
study  (GS-US-334- 2130), in which these probe drugs were administered simultaneously  with no 
effect on their respective exposure as compared with administration alone and thus are sensitive 
to measure changes in OATP and BCRP activity  when administered as a cocktail.
1.4. Risk/Benefit Assessment for the Study
Potential risks of a participant ’s involvement in this study  include AEs related to short -term use 
of filgotinib, ATV , PRA and/or ROS , in addition to the general risks associated with frequent 
laboratory  blood draws. 
An infectious disease pandemic may  pose additional risks to study  drug availability , study  visit 
schedule, and adherence to protocol- specified safety  monitoring or laborat ory assessments. 
There is no anticipated benefit to health y participant s. However, data from this study  will support 
the development of filgotinib for the treatment of chronic inflammatory  diseases (eg ,RA, PsA, 
IBD). All 
participants will be monitored fo r AEs and laboratory  parameters, and eligibility  
criteria will ensure a healthy  participant population. I ndividual participant and study  stopping 
criteria are outlined as an added measure of safet y. Finally , safet y data will be evaluated on an 
ongoing basi s. Taken together with the totality  of the nonclinical toxicology and clinical safet y 
data outlined in the filgotinib IB, the risks to healthy  participant s are considered acceptable.
1.5. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 22 25 Septemeber 20202. OBJECTIVES
The primary  objective of this study  is as follows:
To evaluate the effect of filgotinib on a mixed OATP/CYP3A, OATP/BCRP, and OATP 
substrates using phenotypic probes
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  of multiple filgotinib doses administered alone or in 
combination with probe drugs
Filgotinib 
Protocol GS-US-417-5937 
Gilead Sciences, lnc. 
3. STUDY DESIGN 
3.1. Study Desi gn Final 
Original 
This protoco l describes a Phas e 1, random ized, two- way crossover, open-label, single and 
multiple dose, single ce nter study to evaluate the effect of filgotinib on a mixed OATP/CYP3A , 
OATP/BCRP , and OATP s ubstrates using phenotyp ic prob es in heal thy nonna l partic ipants. Up 
to 30 partic ipants will be enrolled. 
Heal thy surgically sterile male and nonpr egnant, nonlactat ing fe male participants aged 18 
throu gh 55 years will be enro lled into the study. 
An overview of the study design is described below and shown in Fi gure 3-1 and Figure 3-2. 
Treatment A: Single dose of ATV 40 mg, followed by a washout period of 1 day and a single 
dose of the PRA 40 mg/ROS 10 mg cockta il 
Treatment B: Filgotinib 200 mg administered once daily for 11 days, with a single dose of A TV 
40 mg ad ministered on the six th day or a single dose of PRA 40 mg/ROS 10 mg cockta il 
administered on the eig hth day 
Figure 3-1. 
28 Study Schema - Sequence AB 
1 17 24 (±2) 
1 3 7 11 12 13 14 15 16 
Screening 
Admission 6. • 
Clinic Confinement 
Intensive PK sampling 
• Filgotinib 
6. Atorvastatin 
• Pravasta tin + Rosuvastatin 
I Washout 
CON FIDENTIAL ____ _..., ••• 
6. • 
Page 23 e Discharge Follow up 
25 Septemeber 2020 
Filgotinib 
Protocol GS-US-417-5937 Final 
Gilead Sciences, lnc. Original 
Figure 3-2. S tudy Schema -Sequence BA 
3.2. -28 
Screening 
-• 
6. • I -1 
1 5 6 7 8 
Clinic Confinemen t 
Intensive PK sampling 
Filgotinib 
Atorvastatin 
Pravasta tin + Rosuvastatin 
Washout 
Study Drug Administration 11 23 27 (±2) 
18 20 
Follow up 
Please re fer to Section 5.3 for additional infonnation for study drug dosage and admin istration. 
3.3. Duration of Dosin g 
Participants will dose for 13 days, all of which occur during the clinic confin ement. 
3.4. Clinic Confinement 
Following screening and admission proc edures, eligible participants will be confin ed to the study 
center beginning at admission on Day 1 until the comp letion of assessments on Day 17 
(Sequence AB) or Day 23 (Sequence BA). All participants will be contact ed by tele phon e 
7 (± 2) days after last dose for follow up (ie, on Day 24 [± 2] for Sequence AB or on Day 27 
[ ± 2] for Sequence BA). 
3.5. Pharmacokinetic Assessments 
Phannacokinetic assess ments will occur on assigned study days as outlined in Table 6-1 throu gh 
Table 6-2 and in Section 6.5. 
CON FIDENTI AL Page 24 25 Septemeber 2020 
Filgotinib 
Protocol GS-US-417-5937 
Gilead Sciences, lnc. 
3.5.1. Plasma Pharma cokinetic Collection Final 
Original 
Plasma concentrat ions of ATV, PRA, and ROS will be deten nined and PK parameters estimated 
as outlined in Section 6.5.1. Pl asma concentrat ions of filgotinib and its metabo lite (GS-829845) 
may be analyzed . Plasma concentrat ions of metabo lites of probe drugs or filgotinib may be 
analyzed, if applicable. 
3.5.2. Genomic Sample Collection 
A mandatory blood samp le will be collected from all participants who have prov ided consent to 
partici pate in this study . This sample will be collected for the extract ion of DNA for genom ic 
testing and genotyping to identify polymorph isms of drug transporters ( eg, OA TP 1 B 1) . This 
samp le shou ld be collected on Day 1, before admini stration of the first dose of study drug, but 
may be collected at any time during the study, if neccessary . 
3.6. Safety Assessments 
Safety assessments will be perfon ned through the study as outlined in Table 6-1 through 
Table 6-2 and in Section 6.6. 
3.7. E nd of Study 
The end of this study will be the last partici pant's last observat ion ( or visit). 
3.8. Discontinuation Criteria 
Study treatment and/or study procedures may be discont inued in the following instances: 
• Intercurrent illness that would, in the judgment of the invest igator, affect assessments of 
clinical status to a significant degree 
• Unacceptab le toxicity, as defined in the toxic ity management section of the protoco l, or 
toxic ity that, in the judgment of the invest igator, comprom ises the ability to continue 
study-spec ific procedures or is cons idered not to be in the partici pant's best interest 
• Participant requests to discont inue for any reason 
• Participant noncomp liance 
• Pregnancy during the study (refer to Appendix 2) 
• Invest igator discret ion 
• Discont inuation of the study at the request of Gilead, regu latory agency, or an institutional 
review board (IRB) 
CONFIDENT IAL Page 25 25 Septemeber 2020 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 26 25 Septemeber 20203.9. Source Data
The source data for this study will be obtained from electronic data capture ( EDC ), a local 
lab
oratory , and specialt y laboratory  (for PK and/or pharmacod ynamics data) .
3.9.1. Discontinuation
3.9.1.1. Study  Stopping C riteria
If 3 or more participant s in any  group experience the same or similar Grade 3 
treatment -emergent AE or confirmed laboratory  abnormality , unless there is a clear and 
obvious phy siologic explanation for the events (eg
,blood in urine occurring in a 
menstruating female or creatine phosphokinase (CPK )elevation after strenuous exercise, 
etc.), then a review of all safet y data generated in participant s dosed to date will be initiated.
If 2 or more participant s in any  group experience the same or similar Grade 4 
treatment -emergent AE or confirmed laboratory  abnormality , then a review of all safet y data 
generated in participant s dosed to date will be initiated. Dosing will be on hold until the 
review of all the safety  data is completed. If the safety  review determines that it is safe and 
tolerable to continue dosing, stud y drug administration will continue. I f the safet y review 
determines that dosin g should not continue, the study  will be stopped. The decision whether 
or not to complete the full course of stud y medication will be made by the sponsor, in 
consultation with the principal investigator, with disclosure of new information to the study  
participant (s).
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 27 25 Septemeber 20204. PARTICIP ANT POPULA TION
4.1. Number of Participant s and Participant Selection
Approximately  30unique participants will be enrolled in the study ,which include health y 
nonpregnant, nonlactating female and surgicall y sterile male participants 18 through 55 years of 
age, inclusive
4.1.1. Participant 
Replacement
If necessary , replacement participants may be enrolled after discussion and approval from the 
sponsor if participants do not complete all intensive PK procedures or the participant is 
considered nonevaluable . Replacement participants will not be enrolled for participants who 
discontinue the study  due to study  drug -related AEs.
4.2. Inclusion Criteria
Participants must meet all of the following inclusion criteria to be eligible for partic ipation in this 
study :
1)Have the ability  to understand and sign a written informed consent form (ICF), which must 
be obtained prior to initiation of study  procedures
2)Be aged 18through 55years, inclusive ,at screening
3) Be a nonsmoker. The use of nicotine or nicotine -containing products must be discontinued 
90days prior to the first dose of study  drug
4)Have a calculated body  mass index ( BMI ) of≥19.0 and ≤ 30.0 kg/m2at screening
5)Have a creatinine clearance (C Lcr) ≥ 90 mL/min (using the Cockcroft -Gault method 
{Cockcroft 1976 }) based on serum creatinine and actual body  weight as measured at 
screening and upon admission :
Male: (140 Age [years]) (Weight [
kg]) CL cr(mL/min)
72(Serum Creatinine [mg/dL ])
Female: (140 Age [years]) (Weight [kg]) 0.85 CL cr(mL/min)
72(Serum Creatinine [mg/dL ])
6)Female participants of childbearing potential (as defined in Appendix 2) must have a 
negative serum pregnancy  test at screening and a negative urine pregnancy test at 
clinic 
admission .
7)Male participants must be surgicall y sterile
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 28 25 Septemeber 20208)Male participants and female participants ofchildbearing potential who engage in 
heterosexual intercourse must agree to use protocol -specified method(s) of contraception as 
described in Appendix 2.
9)Screening laboratory  evaluations and 12 -lead electrocardiogram (ECG )evaluations must be 
without cli nically  significant abnormalities as assessed b y the investigator.
10)Have liver biometric tests such as alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase, and total bilirubin below the upper limit of 
normal at screening
11)Must be willing and able to co mply  with all study  requirements
12)Must, in the opinion of the investigator, be in good health based upon medical history  and 
physical examination, including vital signs
13)Participants must not have donated blood within 56 days ofstudy  entry  or plasma within 
7days of study  entry  and must refrain from blood donation from clinic admission, 
throughout the stud y period, and continuing for at least 30 days following the last dose of 
study  drug.
4.3. Exclusion Criteria
Participants who meet anyof the following exclusion criteria will not be enrolled in this study :
1)Positive serum pregnancy te st(Female participant) (Appendix 2)
2)Lactating female
3)Have received an y investigational drug /device within 30 day s prior to study  dosing (or within 
5 half -lives of the drug
, whichever is longer)
4)Have c urrent alcohol or substance abuse judged by  the investigator to potentially  interfere 
with participant compliance or participant safety , or a positive drug or alcohol test at 
screening or admission.
5)Have a positive test result for human immunodeficiency  virus t ype 1 (HIV-1) antibody , 
hepatitis B virus (HBV) surface antigen (HBsAg) ,or hepatitis Cvirus (HCV) antibod yat 
screening
6)Have positive Coronaviru s Disease 2019 ( COVID -19) Real-Time Reverse 
Transcriptase -Polymerase Chain Reaction (RT -PCR )testing 
on screening and admission.
7)Have poor venous access that limits phlebotomy
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 29 25 Septemeber 20208)Have taken an y prescription medications or over -the-counter medications, including herbal 
products, within 28 days prior to start of study  drug dosing, with the exception of vitamins 
and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medications
9)Have been treated with sy stemic steroids, immunosuppressant thera pies, or chemotherapeutic 
agents within 3 months prior to s creening or is expected to receive these agents during the 
study  (eg, corticosteroids, immunoglobulins, other immune -or cy tokine -based therapies)
10)Have a history  of any  of the following:
a.Significant serious skin disease, such as but not limited to rash, food allergy , eczema, 
psoriasis, or u rticaria
b.Significant drug sensitivity  or drug allergy  (such as anaphy laxis or hepatoxicity )
c.Known hy persensitivity  to the study  drugs ,their metabolites, or to formulation excipients 
(see Section 5)
d.Significant cardiac disease (including history  of my ocardial infarction based on ECG 
and/or clinical history , any  history  of ventricular tachy cardia, congestive heart failure, or 
dilated cardiom yopath y with left ventricular ejection fraction < 40%), a family  history  of 
long QT syndrome, or unexplained death in an otherwise healthy individual between the 
ages of 1 and 30 years
e.Recurrent s yncope , palpitations, or unexplained dizziness
f.Impla nted defibrillator or pacemaker
g.Liver disease, including Gilbert syndrome
h.
Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid 
hypersecretory  conditi ons requiring prolonged (> 6 months) medical treatment
i.Medical or surgical treatment that permanentl y alteredgastric absorption (eg, gastric or 
intestinal surgery ).A history  of cholecy stectom y is not exclusionary 
11)Have an y serious or active medical or ps ychiatric illness (including depression) that, in the 
opinion of the i nvestigator, would interfere with participant treatment, assessment, or 
compliance with the protocol. This would include renal, cardiac, hematological, hepatic, 
pulmonary  (including chro nic asthma), endocrine (including diabetes), central nervous, 
gastrointestinal (including an ulcer), vascular, metabolic (thy roid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, or malignancy  that are clinically  significant or 
requiring treatment .
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 30 25 Septemeber 20205. STUDY  DRUGS
5.1. Randomization , Blinding, and Treatment Codes Access
5.1.1. Randomization
Following screening and admission assessments, eligible participants will be confined to the 
study  center. Once eligibility  has been confirmed and following completion of the admission 
study  procedures, eligible participants will be randomized at 1:1 ratio on the evening of Day 1 
to receive 1 of2 treatment sequences starting on Day  1.
All screening and admi ssion (Day 1) tests and procedures must be completed and reviewed b y 
the 
investigator prior to the administration of the first dose of study  drug on Day 1. It is the 
responsibility  of the investigator to ensure that the participant is eligible for the study  prior to 
enrollment. Once a participant number has been assigned to a participant , it will not be 
reassigned to another participant . If necessary , replacement participants may  be enrolled after 
discussion and approval from the sponsor. 
5.1.2. Blinding
Blinding of treatment assignments or data will not be performed in this study .
5.2. Description and Handling of Filgotinib
5.2.1. Formulation
Filgotinib is provided as 200 mg strength tablets. Filgotinib tablets, 200 mg, are beige, debossed 
with “GSI”on one side and “200” on the other, capsule -shaped, film - coated tablets. Each tablet 
contains the equivalent of 200 mg filgotinib free base in the form of filgotinib maleate. In 
addition to the active ingredient, filgotinib tablets contain the following i nactive ingredients: 
microcry stalline cellulose, lactose monohy drate, fumaric acid, pregelatinized starch, silicon 
dioxide, magnesium stearate, macrogol/PEG 3350, poly vinyl alcohol, talc, titanium dioxide, iron 
oxide y ellow, and iron oxide red.
5.2.2. Packaging and Labeling
Filgotinib tablets, 200 mg, are packaged in white, high densit y polyeth ylene (HDPE) bottles. 
Each bottle contains 30 tablets, silica gel desiccant and poly ester packing material. Each bottle is 
enclosed with a white, continuous thread, child-r esistant poly propy lene screw cap fitted with an 
induction- sealed and aluminum -faced liner.
Sufficient quantities of filgotinib tablets, 200 mg to complete the entire study  will be shipped to 
the investigator or qualified designee from the Gilead Supply  Man agement Team.
Study  drugs to be distributed to the participating site shall be labeled to meet applicable 
requirements of the United States FDA.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 31 25 Septemeber 20205.2.3. Storage and Handling
Filgotinib tablets should be stored at controlled room temperature of 25 °C (77 °F); excur sions 
are permitted between 15 °C and 30 °C (59 °F to 86 °F).
Storage conditions are specified on the label. Until dispensed to the participants, all drug 
products should be stored in a securely locked area, accessible onl y to authorized site personnel. 
Toensure the stabilit y of the study drug and to ensure proper product identification, the drug 
product should not be stored in a container other than the container in which they  are supplied. 
Consideration should be given to handling, preparation, and dispo sal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure when handling.
5.3. Description and Handling of Commercially Available Drugs
Commercial product of ATV , PRA ,and ROSwill be used for the stud y. Further information 
regarding storage and handling are available in the Prescribing Information for these commercial 
products.
5.4. Dosage and Administration of Study Drug
Following completion of screening and admission assessments (Day  1), eligible participants 
will be randomized the evening of Day  1 to receive 1 of 2 treatment sequences starting on 
Day 1:
OATP/CYP3A substrate: ATV 40 mg
OATP substrate: PRA 40 mg
OATP/BCRP substrate: ROS 10 mg
Pravastatin/Rosuvastatin (PRA/ROS) will be coadministered as a probe cocktail
.
Treatment A: Single dose of ATV 40 mg, followed by  a washout period of one day  followed b y
a single dose of the PRA 40 mg /ROS 10 mg cocktail 
Treatment B: Filgotinib 200 mg administered once daily for 1 1 day s, with a single dose of ATV 
40mg administered on the sixth day followed b ya single dose of PRA 40 mg /ROS 10 mg
cocktail administered on the eighth day
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 32 25 Septemeber 2020Sequence Days
ABPeriod 1 Period 2
1 2 3 4-67-
11 12 13 14 15- 17
ATV WO PRA +ROS WO FILFIL
+
ATVFILFIL + PRA + 
ROSFIL
BAPeriod 1 Period 2
1-5 6 7 89-
1112-
17 18
19 20
FILFIL + 
ATVFIL FIL +PRA +ROS FIL WO ATV WOPRA + 
ROS
FIL  filgotinib; ATV  atorvastatin; PRA  pravastatin; ROS  rosuvastatin ; WO Washout
5.5. Fasting and Meals
All study  treatments will be administered orally at the study  center in the morning at 
approximately  the same time on each day  with 240 mL  of water following an overnight fast 
(nofood or drink, except water, for at least 10hours) . On non- intensive PK days, participants 
will continue to fast for 2 hours postdose relative to study  drug dosing.
On the day s of intensive PKsampling (Day s 1, 3, 12, and 14 for Sequence AB and Day s 6, 8, 18, 
and 20 for Sequence BA) , the study  drug will be administered in the morning following an 
overnight fast (no food or drink ,except water , for at least 10 hours ).On intensive PK day s, 
participants will be restricted from food intake until after collection of the 4- hour blood draw. 
Participants will continue to fast until af ter collection of the 4 -hour PK sam ple, relative to stud y 
drug dosing. Additionally ,participants will be restricted from water consumption 1 hour before 
and until 2hours after dosing, except for the 240 mL given with the study  treatment (s). After 
collection of the 4 -hour PK sample, participants will be provided with a standardized meal.
All meals and/or snacks given to participants during their stay
 in the clinical study  facility  will be 
standardized for all participants and should be similar in ca lorie and fat content and taken at 
approximately  the same time each day . All meals provided must be approved by  the sponsor. 
Components of meals (eg, margarine, jelly , bread) should be given to participants in individual 
portions (eg, 1 tablespoon) per the approved meal schedule. The provision of meal components 
in bulk (eg, a jar of jelly  for participants to share) should not be practiced. All meals should be 
given at approximately  the same time each day  (eg, 07:30, 12:00, 18:00).
5.6. Dispensing , Accountabilit y, and Disposal or Return ofStudy Drug
The investigator (or designee, eg,study  center pharmacist) will acknowledge receipt of the study  
drug (after reviewing the shipment’s content and condition) from Gilead (or designee). The 
i
nvestigator will maintain an accurate inventory  of all study  drug(s). Each dose of the study  
drug(s) administered at the study  center will be administered by  qualified study  center 
staff. The 
dose of study  drug(s) administered to participants in the clinic under the supervision of staff will 
be accuratel y recorded on the Study  Drug Accountability  form provided b y Gilead (or on 
equivalent documentation maintained by  the study  center), which indicates the date and quantit y 
of each dosage formulation dispensed to individual participant s.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 33 25 Septemeber 2020Gilead recommends that used and unused study  drug should be destroy ed at the site. If the site 
has an appropriate Standard Operating Procedure ( SOP)for drug dest ruction as determined b y 
Gilead, the site may  destroy  used (empt y or partially empt y) and unused study  drug supplies in 
accordance with that site’s approved SOP . A cop y of the site’s approved SOP will be obtained 
for the 
eTMF . If study  drug is destro yed onsite, the investigator must mai ntain accurate records 
for all study  drug s destroy ed. Records must show the identification and quantity of each unit 
destroy ed, the method of destruction, and the person who disposed of the study  drug . Upon study  
completion, copies of the study  drug accoun tability  records must be filed at the site. Another 
copy  will be returned to Gilead. 
If the site does not have an appropriate SOP for drug destruction, used and unused study  drug
supplies are to be sent to the designated disposal facility  for destruction. The study  monitor will 
provide instructions for return.
The study  monitor will review study  drug supplies and associated records at periodic intervals.
For both disposal options listed above , the study  monitor must first perform drug accountability  
during amonitoring visit.
5.7. Concomitant Medications and Other Protocol Restrictions
5.7.1. Concomitant Medications 
The following medications are excluded while participants are participating in the study (from 
screening until discharge) :
Any prescription medications an d over -the-counter medications
, including herbal products 
and antacids ,with the exception of vitamins, and/or acetaminophen and/or ibuprofen and/or 
hormonal contraceptive medications. However, the short- term use of topical hy drocortisone 
cream or A D ointment to treat minor skin irritation due to ECG leads will be allowed. If a 
participant requires use of a disallowed medication, a request for such use must be reviewed 
by the 
sponsor and if approved, participants may  continue to participate in the st udy.
Any and all illegal or illicit drug use, including use of prescription drugs outside the care of 
the prescribing ph ysician .
5.7.2. Other Protocol Restrictions
Participants will be required to refrain from the consumption of food and beverages 
containing alco hol 72 hours prior to the first dose of study  drug and during the course of the 
study  through discharge.
Participants will be required to refrain from the use of nicotine or nicotine -containing 
products 90 days prior to first dose of study  drug and during the course of the study  through 
discharge . 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 34 25 Septemeber 2020Participants will be required to refrain from consumption of grapefruit juice, grapefruits, and 
Seville orange juice 72 hours prior to the first dose of study  drug and during the course of the 
study  through discharge .
While confined at the study  center, tea, coffee, chocolate, and other foods and beverages 
containing caffeine and other methy l xanthines will be prohibited on each dosing day . Atall 
other times, caffeine -containing beverages and foodstuffs may  be se rved or withheld in 
accordance with normal study  center practice. Caffeine -containing beverages and foodstuffs 
will not be restricted while participants are outside of the clinic.
Participants will be encouraged to avoid strenuous or prolonged exercise, as well as saunas, 
steambaths, and sunbathing or other prolonged ultraviolet exposure ( eg,in a tanning salon )
from the 
screening evaluation and during the course of the stud y through discharge , as these 
activities are known to affect certain clinical laboratory  test parameters (e g,creatine kinase ) 
and will provide false indicators of a potentiall y treatment -related toxicity . 
Upon every  admission to the clinic, each participant will be questioned as to their compliance 
with the above protocol restrict
ions. If a participant is unable to comply  with any  of the 
restrictions described above, the participant’s continued participation in the study  will be 
reevaluated b y the investigator in consultation with the s ponsor.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 35 25 Septemeber 20206. STUDY  ASSESSMENTS
The study  procedures to be conducted for each participant enrolled in the study  are detailed 
below .
Any deviation from protocol procedures should be noted in the participant ’s clinical chart and 
appropriate electronic case report f orms ( eCRFs ). In addition, the sponsor should be promptly  
notified of an y protocol deviations. 
The study  center will not initiate dosing until the following have all been met :
The I RB ha sreviewed and approved the stud y and the informed consent document .
All requested regulatory  documen ts have been submitted to and approved by  Gilead .
A master services agreement and/or study 
agreement is executed.
The study  initiation meeting has been conducted by  the Gilead (or designee).
The initiation meeting will include but is not limited to a review of the protocol, the IB, study  
drugs, and investigator responsibilities.
Documentation of the personally  signed and dated ICFforeach participant , using the 
study -specific ,IRBapproved I CF, is required before initiating the screening process. 
6.1. Participant Enrollment and Treatment Assignment
Entry  into screening does not guarantee enrollment into the study . In order to manage the total 
study enrollment, Gilead, at its sole discretion, may  suspend screening and/or enrollment only  a 
single site at an y time .
It is the responsibility  of the investigator to ensure that participants are eligible to participate in 
the study  prior to enrollment and continue to remain eligible throughout the study .
Once the ICFhas been obtained, all screening and admission tests and assessments have been 
assessed, and stud y eligibility  has been confirmed, participants will be enrolled to receive stud y 
drug on Day 1.
Participants will receive the study  treatments as described in Section 5.3.
Filgotinb
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 36 24 Septemeber 2020Table 6-1. Schedule of Assessments (Sequence AB)
Study 
Procedure
Screeninga
Admission
Day −1
Day 1
Day 2
Day 3
Day 4
Day 5 Day 6
Day 7
Day 8 Day 9 Day 10
Day 11
Day 12
Day 13 Day 14
Day 15
Day 16
Discharge
Day 17b
Follow -Upc
Day 24± 2
ETdWritten 
Informed 
ConsentX
Medical 
History X
Complete 
Physical 
ExaminationX X X X X
Symptom
Driven Physical 
ExaminationeX X X X X X X X X X X X X X X
Height X
Weight X X X X X X
Vital SignsfX X X X X X X X X X X X
HIV1, HBV, 
and HCV 
TestinggX
HematologygX X X X X X X X X X X X
ChemistrygX X X X X X X X X X X X
Creatine 
phosphokinase 
(CPK)X X X X X X X X X X X X
Calculated 
Creatinine 
ClearanceX X X X X X
UrinalysisgX X X X X X X X X X X X
Serum 
Pregnancy 
Test g,hX X X X
Urine 
Pregnancy Test
hX X
Filgotinb
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 37 24 Septemeber 2020Study 
Procedure
Screeninga
Admission
Day −1
Day 1
Day 2
Day 3
Day 4
Day 5 Day 6
Day 7
Day 8 Day 9 Day 10
Day 11
Day 12
Day 13 Day 14
Day 15
Day 16
Discharge
Day 17b
Follow -Upc
Day 24± 2
ETdFollicle
Stimulating 
Hormone 
(FSH)g,hX
Thyroid 
Stimulating 
Hormone 
(TSH)ghX
Urine Drug and 
Alcohol 
ScreengX X
12Lead ECG X
COVID 19
RTPCRX X
Randomization/
Enrollmenti X
Study Drug 
Administrationj X X X X X X X X X X X X X
Intensive 
Plasma PKk X X X X
Genotype 
Testingl X
Review Study 
RestrictionsX X X X
Clinic 
ConfinementX X X X X X X X X X X X X X X X X X
Review AEs & 
Concomitant 
MedicationsmX X X X X X X X X X X X X X X X X X X X X
AE  adverse event; ECG  electrocardiogram; COVID 19 RT PCRa real time reverse transcription polymerase chain reaction (rTT PCR) test for the qualitative detection of 
nucleic acid from SARS CoV 2
eCRF electronic case report form; ET  early termination; HBV  hepatitis B virus; HCV  hepatitis C virus; HIV 1  human immunodeficiency virus type 1 and type 2; 
PE physical examination; PG  pharmacogenomic; PK  pharmacokinetic(s
a. Prospective participant should be screened no more than 28 days prior to administration of the first dose of study drug.
Filgotinb
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 38 24 Septemeber 2020b. Participants will be discharged from the clinic on Day 17 (Sequence AB) following all assessments.
c. 7 (± 2)days after the last administration of study drug, all participants will be contacted via telephone to review and document A Es and concomitant medications 
d. Early termination (ET) assessments will be performed within 72 hours of prematurely discontinuing from th e study.
e. Symptom driven PEs will be performed during confinement as needed, based on reported signs and symptoms.
f. Vital signs include blood pressure, heart rate, respiration rate, and body temperature.
g. See Section 6.6.5 for specifics.
h. Females of childbearing potential only.
i. On Day 1,participants will be randomized the evening to receive 1 of 2 treatment sequences starting on Day 1. 
j. See Section 5.4for specifics.
k. Intensive PK sampling will occur relative to the morning dosing of study drug at the time points as outlined in Section 6.5.1 .
l. Blood sample should be collected on Day 1, but may be collected at any time during the study, if necessary
m. From the time of obtaining informed consent through the first administration of study drug, record all SAEs, as well as any nonserious AEs related to pr otocol mandated 
procedures, on the AE eCRF. All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical history, are to be 
captured on the medical history eCRF. See Section 7, Adverse Events and Toxicity Management, for additional details.
Table 6-2. Schedule of Assessments (Sequence BA)
Study 
Procedure
Screeninga
Admission
Day −1
Day 1
Day 2
Day 3 Day 4
Day 5
Day 6 Day 7
Day 8 Day 9
Day 10
Day 11 Day 12 Day 13 Day 14 Day 15
Day 16
Day 17 Day 18 Day 19 Day 20 Day 21
Day 22
Discharge
Day 23b
Follow -Upc
Day 27 ± 2
ETdWritten 
Informed 
ConsentX
Medical 
History X
Complete 
Physical 
ExaminationX X X X X
Symptom
Driven 
Physical 
ExaminationeX X X X X X X X X X X X X X X X X X X X X X
Height X
Weight X X X X X X X
Vital SignsfX X X X X X X X X X X X X
HIV1, HBV, 
and HCV 
TestinggX
HematologygX X X X X X X X X X X X X
Filgotinb
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 39 24 Septemeber 2020Study 
Procedure
Screeninga
Admission
Day −1
Day 1
Day 2
Day 3 Day 4
Day 5
Day 6 Day 7
Day 8 Day 9
Day 10
Day 11 Day 12 Day 13 Day 14 Day 15
Day 16
Day 17 Day 18 Day 19 Day 20 Day 21
Day 22
Discharge
Day 23b
Follow -Upc
Day 27 ± 2
ETdChemistrygX X X X X X X X X X X X X
Creatine 
phosphokinase 
(CPK)X X X X X X X X X X X X X
Calculated 
Creatinine 
ClearanceX X X X X X X
UrinalysisgX X X X X X X X X X X X X
Urine 
Pregnancy TestX X
Follicle
Stimulating 
Hormone 
(FSH) g,hX
Thyroid 
Stimulating 
Hormone 
(TSH)ghX
Serum 
Pregnancy 
Testg , hX X X X X
Urine Drug and 
Alcohol 
ScreengX X
12Lead ECG X
COVID 19 
RTPCRX X
Randomization
/Enrollmenti X
Study Drug 
Administrationj X X X X X X X X X X X X X
Intensive 
Plasma PKk X X X X
Genotype 
Testingl X
Filgotinb
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 40 24 Septemeber 2020Study 
Procedure
Screeninga
Admission
Day −1
Day 1
Day 2
Day 3 Day 4
Day 5
Day 6 Day 7
Day 8 Day 9
Day 10
Day 11 Day 12 Day 13 Day 14 Day 15
Day 16
Day 17 Day 18 Day 19 Day 20 Day 21
Day 22
Discharge
Day 23b
Follow -Upc
Day 27 ± 2
ETdReview Study 
RestrictionsX X X X
Clinic 
ConfinementX X X X X X X X X X X X X X X X X X X X X X X X
Review AEs & 
Concomitant 
MedicationsmX X X X X X X X X X X X X X X X X X X X X X X X X X X
AE  adverse event; ECG  electrocardiogram; COVID 19 RT PCR a real time reverse transcription polymerase chain reaction (rTT PCR) test for the qualitative detection of 
nucleic acid from SARS CoV 2
eCRF  electronic case report form; ET  early termination; HBV  hepatitis B virus; HCV  hepatitis C virus; HIV 1  human immunodeficiency virus type 1 and type 2; PE 
physical examination; PG  pharmacogenomic; PK  pharmacokinetic(s) ; COVID 19 RT PCR a real time reverse transcription polymerase chain reaction (rTT PCR) test for the 
qualitative detection of nucleic acid from SARS CoV 2
a. Prospective participants should be screened no more than 28 days prior to administration of the first dose of study drug.
b. Participants will be discharged from the clinic on Day 23(Sequence BA) following all assessments.
c. 7 (±2)days after the last administration of study drug , all participants will be contacted via telephone to review and document AEs and concomitant medications .
d. Early termination ( ET) assessments will be performed within 72 hours of prematurely discontinuing from the study.
e. Symptom driven PEs will be performed during confinement as needed, based on reported signs and symptoms.
f. Vital signs include blood pressure, heart rate, respiration rate, and body temperature .
g. See Section 6.6.5 for specifics.
h. Females of childbearing potential only.
i. On Day 1,participants will be randomized the evening to receive 1 of 2 treatment seque nces starting on Day 1 .
j. See Section 5.4for specifics.
k. Intensive PK sampling will occur relative to the morning dosing of study drug at the time points as outlined in Section 6.5.1 .
l. Blood samples should be collected on Day 1, but may be collected at any time during the study, if necessary
m. From the time of obtaining informed consent through the first administration of study drug , record all SAEs, as well as any nonserious AEs related to protocol mandated 
procedures ,on the AE eCRF . All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical his tory,are to be 
captured on the medical history eCRF. See Section 7, Adverse Events and Toxicity Management ,for additional details.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 41 25 Septemeber 20206.2. Pretreatment Assessments
6.2.1. Screening Assessments
Prospective participants should be screened no more than 28 days prior to administration of the 
first dose of study  drug. If aparticipant does not begin the treatment phase within this 28 -day 
window, all screening evaluation procedures must be repeated. Screening lab oratory  assessment s 
may be repeated once within 28 days prior to administration of study  drug to rule out laboratory  
error.
A sufficient number of participants will be screened to identify  planned number of participants 
for randomization
.
Participants should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earl ier, as appropriate, on the evening prior to the s creening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Written informed consent must be obtained from each participant before initiation of any
screening procedure. After a participant has provided informed consent, the i nvestigator and 
other study  personnel will determine if the participant is eligible for participation in the study . 
This assessment will include a review of the inclusion/exclusion c riteria and completion of all 
screening procedures as outlined in Table 6-1through Table 6-2and described in the following 
text. 
Eligible 
participants meeting all of the inclusion criteria and none of the exclusion criteria will be 
instructed on all protocol requirements ,including the restrictions on concomitant medication 
usage and other substances as well as consumption of food or beverages containing alcohol, 
caffeine, or xanthine. Participants will be asked to arrive at the study  center on Day 1for 
admission assessm ents.
From the time of obtaining informed consent through the first administration of study  drug , 
record all serious adverse events ( SAEs ), as well as any  adverse events related to 
protocol -mandated procedures on the adver se events case report form (AE eCRF). All other 
untoward medical occurrences observed during the screening period, including exacerbation or 
changes in medical history are to be captured on the medical histor y eCRF. See Section 7,
Adverse Events and Toxicity  Management ,for additional details.
6.2.2. Admission Assessments
6.2.2.1. Admission
Participants should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the admission 
visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 42 25 Septemeber 2020Participants meeting all eligibility  criteria following the screening evaluation will return to the 
clinic for admission assessments on Day 1. The admission evaluations and/or procedures are 
outlined in Table 6-1through Table 6-2.
Prior to dosing on Day 1, the results of the clinical and laboratory
 evaluations (as described in 
Table 6-1through Table 6-2)must be reviewed b y the i nvestigator to confirm the continued 
eligibility  of each participant to participate in the study . At the time of randomization , 
participants will be assigned a 
particip antnumber as described in Section 5.1. P articipants will 
remain confined to the study  clinic for the duration as described in Section 6.2.2.2 and Table 6-1
through Table 6-2.
Prior to study  drug administration, re cord an y SAEs and all AEs related to protocol
-mandated 
procedures. After drug administration, report all AEs and SAEs.
6.2.2.2. Clinic Confinement
Participants will be confined to the study  clinic starting at on Day 1until completion of 
assessments on Day 17 (Sequence AB )or Day  23 (Sequence BA) .
6.3. Check -in Assessments
Following completion of screening and Day 1assessments, eligible participants will be 
randomized the evening of Day  
1to receive 1 of 2 treatment sequences starting on Day  1in 
Section 5.4.
6.4. Treatment Assessments
Study  treatment assessments are outlined in Table 6-1through Table 6-2.
6.5. Phar macokinetic 
Assessments
6.5.1. Plasma PK Collection
Plasma concentrations of ATV , PRA , and ROS will be determined and PK parameters evaluated . 
Plasma concentrations of filgotinib and its metabolite (GS -829845) may  be anal yzed.Plasma 
concentrations of metabolites of probe drugs or filgotinib may be anal yzed, if applicable.
Intensive PK sampling will occur relative to dos ing of study  drug at the following time points:
Sequence AB:
Days 1 and 12: 0 (pre dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 2 4, 36, and 
48hours postdose
Days 3 and 14: 0 (pre dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, and 72 hours 
postdose
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 43 25 Septemeber 2020Sequence BA: 
Days 6 and 18: 0 (pre dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 
48hours postdose
Days 8 and 20: 0 (pre dose, ≤ 5 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, and 72 hours 
postdose
6.6. Safety Assessments
Safety  will be evaluated throughout the study . Refer to Table 6-1through Table 6-2for the 
schedule of assessments.
6.6.1. Electrocardiogram Assessment
Participants should rest quietly  in the supine position for a minimum of 10 minutes prior to each 
scheduled ECG acquisition and should remain in that position until the recording is complete.
There should 
be no environmental distractions ( including TV, radio, video games, and 
conversation) while the participants are resting prior to and during the recordings. 
Electrocardiograms will be recorded using the site’s standard ECG equipment . AllECGs will be 
obtained using instruments that analy ze data using the same algorithms and produce the same 
data for interpretation. Electrode placement will be performed according to the method of 
Wilson, Goldberger, and Einthoven with a check to confirm that the aVR lead is not inverted.
The investigator or other qualified individuals at the study  center will review ECGs to assess for 
changes in ECG intervals and morphology  as compared with pretreatm ent ECGs. The ECG 
interval measurements output by  the machine will be used for bedside safety  monitoring.
Collection of additional ECGs for routine safet y monitoring at additional time points or day s is at 
the discretion of the investigator based on GCP .
6.6.2. Physical Examination
Physical examinations conducted throughout the study  will be a complete phy sical examination 
or a s ymptom -driven physical examination ,as outlined in Table 6-1through Table 6-2. The 
complete ph ysical examination conducted at s creening will also include the following 
assessments:
Review medical hi story , including history  of allergies, prior and current use of nicotine or 
nicotine -containing products, alcohol and illegal drug use ,and prior (within 30 days) and 
current medication use
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 44 25 Septemeber 20206.6.3. Vital Signs
Vital sign measurements include blood pressure, heart rate,respiratory  rate, and body  
temperature and should be taken in the supine position. Participant position for measurement 
should be kept consistent throughout the stud y. Refer to Table 6
-1through Table 6-2for vital 
signs collection time points.
6.6.4. Body Mass Index
Height and weight will be coll
ected at screening for calculation of BMI for inclusion criteria.
6.6.5. Clinical Laboratory Tests/Assessments
Blood and urine samples for safety  evaluations will be collected throughout the study  as outlined 
in Table 6-1through Table 6-2.
6.6.5.1. Blood 
Sampling
Blood samples will be collected for the following laboratory  anal yses:
Hematology : Hematocrit, hemoglobin, platelet count, red blood cell count , white blood cell
count with dif ferential (absolute and percentage), including l ymphocy tes, monocy tes, 
neutrophils, eosinophils, basophils, and mean corpuscular volume 
Chemistry  (fasting): alkaline phosphatase, AST, AL T, total bilirubin, direct and indirect 
bilirubin, total cholesterol, high-densit y lipoprotein, low -density  lipoprotein, trigl ycerides, 
total protein, albumin, lactic acid deh ydrogenase, CPK, bicarbonate, blood urea nitrogen, 
calcium, chloride, creatinine (see below), glucose, phosphorus, magnesium, potassium, 
sodium, uric acid, and amy lase (reflex lipase testing is performed in participants with total 
amylase > 1.
5 ×upper limit of normal )
Serum pregnancy  test (females of childbearing potential only )
Follicle -stimulating hormone testing (screening only ):females who have ceased 
menstruating for ≥
12months but do not have documentation of ovarian hormonal failure
only
Thyroid stimulating hormone testing (screening only )
HIV-1, HBV, and HCV testing ( screening only )
COVID -
19RT-PCR testing will be conducted and reviewed per site specific policy  at 
screening, admission, and as needed during the study . Alternativel y, a comp arable test may  
be used after consultation with the Sponsor. 
Filgotinib 
Protocol GS-US-417-5937 
Gilead Sciences, lnc. 
6.6.5.2. Urine Samples Final 
Original 
Urine samples will be collected for urinalysis, urine pregnancy (females only) and alcohol and 
drug scree n assess ments. 
6.6.6. Creatinine Clearance 
Weight will be collected at the times shown in Table 6-1 through Table 6-2 to calculate CLcr. 
6.6.7. Adverse Events /Concomitant Medications /Protocol Restrictions 
Evaluation for AEs, review of conco mitant medi cations, and review of protoco l restrictions will 
occur at the times shown in Table 6-1 through Table 6-2 . See Section 7 for more infonnation 
regar ding AEs and Sections 4.3 and 5.7.1 for more infon nation about conco mitant medications. 
6.7. Posttreatment Assessments 
All partic ipants will be contacte d by telepho ne 7 d ays ± 2 d ays after last dose of study drug for 
follow up(ie, on Day 24 [± 2] for Sequence AB or Day 27 [± 2] for Sequence BA). Study 
proce dures and assess ments are outlined in Table 6-1 and Table 6-2 . 
6.8. Assessments for Early Discontinuation from Study 
If a participant discont inues study treatment d osing (see Section 3.8), for example as a result of 
an AE, every attempt shou ld be made to keep the participant and continue to perfon n proce dures 
for stabilization per the investigator. Evaluations indicating abnon n al results believed to be 
poss ibly or probab ly related to study treatment at the early tennination visit sh ould be repeate d 
week ly or as often as deemed appropr iate by the invest igator until the abnon n ality resolves, 
returns to base line visit l evels, or is otherw ise explained. 
If the participant wi thdraws consent from the study, the ET evaluations and/or proce dures 
outlined in Table 6-1 through Table 6-2 shou ld be perfon n ed wi thin 72 hours of pennanently 
discont inuing the study. 
CONFI DENT IAL Page 45 25 Septemeber 2020 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 46 25 Septemeber 20207. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events and Serious Adverse Events
7.1.1. Adverse Events
An AE is an y untoward medical occurrence in a clinical study participant administered a study  
drug, which does not necessarily  have a causal relationship with the treatment. An AE can ,
therefore ,be any  unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a study  drug , whether or not considered related to the study  drug . Adverse events
may also include pre treatment or posttreatment complications that occur as a result of 
protocol -specified procedures, or special situations (Section 7.1.3). 
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusion. 
The condition that led to the procedure may  be an AEand must be reported.
Pre
existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (eg, hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.1.3 )
Any medical condition or clinically  significant laboratory  abno rmality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is c onsidered to be pre existing and should be documented medical history .
Preexisting events that increase in severity  or change in nature after stud y drug initiation or 
during or as a consequence of participation in the clinical study  will also be considered AEs.
7.1.2. Serious Adverse Events
AnSAE is defined as an event that, at any dose, results in the following:
Death
A life-threatening situation (Note: The term “life -threatening” in the definition of “serious” 
refers to an event in which the participant was at risk of death at the time of the event; it does 
not refer to an event that hy pothetically  might have caused death if it were more severe.)
Inpatient hospitalization or prolongation of existing hospitalization
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 47 25 Septemeber 2020Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction ;such events may not be immediately  
life-threatening or result in death or hospitalization but may jeopardize the participant or may  
require intervention to prevent 1 of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a re portable 
under expedited reporting rules. Examples of medically
 important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development o fdrug dependency  or 
drug abuse.
7.1.3. Study Drugs and Gilead Concomitant Therapy Special Situations Reports
Special situation reports (SSRs) include all reports of medication error, abuse, misuse, overdose, 
occupational exposure, drug interactions, exposure via breastfeeding, unexpected benefit, 
transmission of infectious agents via the product, counterfeit of falsified medicine, and 
pregnancy  regardless of an associated AE.
Medication error is an y unintentional error in the prescribing, dispensing, preparation for 
administration or administration of a study drug while the medication is in the control of a health 
care professional, patient, or consumer. Medication errors may  be classified as a medication error 
without an AE, which includes situations of missed do se, medication error with an AE, 
intercepted medication error, or potential medication error.
Abuse is defined as persistent or sporadic intentional excessive use of a study  drug b y a 
participant .
Misuse is defined as an y intentional and inappropriate use of a stud y drug that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a stud y 
drug given per administration or cumulatively  whic h is above the maximum recommended dose 
as per protocol or in the product label ing(as it applies to the daily  dose of the participant in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the participant has taken the excess dose(s). Overdose cannot be established 
when the participant cannot account for the discrepancy , except in cases in which the 
investigator has reason to suspect that the participant has taken the additional dose(s).
Occu pational exposure is defined as exposure to a study  drug as a result of one’s professional or 
nonprofessional occupation.
Drug interaction is defined as an y drug/drug, drug/food, or drug/device interaction.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 48 25 Septemeber 2020Unexpected benefit is defined as an unintended therapeutic effect where the results are judged to 
be desirable and beneficial. 
Transmission of infectious agents is defined as any  suspected transmission of an infected agent 
through a Gilead stud y drug.
Counterfeit or falsified medicine is defined as a ny study  drug with a false representation of 
(a)its identity , (b) its source, or (c) its history .
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified s ubinvestigator is responsible for assessing the relationship to the 
study  drug using clinical judgment and the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug . For SAEs, an 
alternative causality  must be provided (eg, preexisting condition, underl ying disease, 
intercurrent illness, concomitant medication).
Yes:There is reasonable possibility  that the AE may have been caused by  the study  drug .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
Therelationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a resu lt of protocol procedures (eg, venipun
cture) .
7.2.2. Assessment of Severity 
The severit y of AEs will be graded using the Common Terminology  Criteria for Adverse Events
(CTCAE )Toxicity  Grading Scale, Version 5. For each episode, the highest grade attained should
be reported as defined in the Toxicity  Grading Scale ( Appendix 4).
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 49 25 Septemeber 20207.3. Investigator Reporting Requirements and Instructions
7.3.1. Requirements for Collection Prior to Study Drug Initiation
After obtaining informed consent, but prior to initiation of study  drug , the following ty pes of 
events must be reported on the applicable eCRFs: all SAEs and AEs related to 
protocol -mandated procedures.
7.3.2. Adverse Events
Following initiation of study  treatment , collect all AEs, regardless of cause or relationship, until 
30days afte r last administration of study  drug and report to the eCRF database as instructed.
All AEs should be followed up until resolution or until the AEis stable, if possible. Gilead may  
request that certain AEs be followed bey
ond the protocol -defined follow -up period.
7.3.3. Serious Adverse Events
All SAE and death, regardless of cause or relationship, that occurs after the participant
firstconsents to participate in the study  (ie,signing the informed consent) and throughout the 
duration of the study , until 30 day s after last administration of study  drug must be reported on the 
applicable eCRFs and to Global Patient Safety  (GLPS )as instructed below in this section. This 
also includes an y SAEs resulting from protocol
-associated procedures performed after informed 
consent is signed.
Investigators are not obligated to activel y seek SAEs after the protocol -defined follow -up perio d;
however, if aninvestigator learns of any  SAEs that occur after the protocol -defined follow -
up 
period has concluded and the event is deemed r elevant to the use of the study  drug , the 
investigator should promptly  document and report the event to GLPS
.
Instructions for reporting SAEs are described in Section 7.4.1.
7.3.4.
Study Drug Special Situations Reports
All study  drug SSRs that occur from study  drug initiation and throughout the duration of the 
study , including the posttreatment follow- up visit, must be reported to GLPS (Section 7.4.2). 
Adverse events and SAEs resulting from SSRs must be reported in accordance to the AE and 
SAE reporting guidance (Section 7.3).
7.3.5. Concomitant Therapy Reports
7.3.5.1. Gilead Concomitant Therapy  Special Situations Report
Special situation reports involving a Gilead concomitant therapy (not con sidered study  drug), 
that occurs after the participant first consents to participate in the study  (ie,signing the informed 
consent) and throughout the duration of the stud y, including the posttreatment follow
-up phone 
callmust be reported to GLPSutilizi ng the paper SSR (Section 7.4.2.3).
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 50 25 Septemeber 20207.3.5.2. Non-Gilead Concomitant Therap y Report
Special situations involving non -Gilead concomitant medications do not need to be reported on 
the SSR form; however, for special situations that result in AEs due to a non-Gilead concomitant 
medication, the AE should be reported on the AE form. 
Anyinappropriate use of concomitant medications prohibited by this protocol should not be 
reported a s “misuse,” but may be more appropriately documented as a protocol deviation.
All clinical sequelae in relation to these SSRs will be reported as AEs or SAEs at the same time 
using the AE eCRF and/or the SAE report form. Deta ilsofthesymptoms and signs, clinical 
management, and outcome will be reported, when available.
7.4. Reporting Process for Serious Adverse Events and Special Situation Reports
7.4.1. Serious Adverse Event Reporting Process
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be transmitted by  email or fax when requested and applicable. 
Transmission of such documents should occur without personal participant identification, 
maintaining the traceability  of a document to the participa ntidentifiers.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the participant ’s eCRF and th e SAE narrative section of the Safet y 
Report Form eCRF.
7.4.1.1. Paper Serious Adverse Event Reporting Process
All SAEs will be recorded on the SAE report form and transmitted by emailing or faxing the 
report form within 24 hours of the investigator’s knowledge of the event to the attention of 
Gilead 
GLPS from ICF signature throughout the duration of the stud y, including the 
protocol -required posttreatment follow- up period.
Gilead GLPS: Gilead GLPS 
Email  
or
Fax: 
PPD
PPD
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 51 25 Septemeber 20207.4.2. Special Situations Reporting Process 
7.4.2.1. Paper Special Situations Reporting Process for Study  Drug
All SSRs will be recorded on the special situations report form and transmitted by emailing 
or faxing the report form within 24 hours of the investigator’s knowledge of the event to the 
attention of Gilead GLPS from study drug initiation throughout the dur ation of the study, 
including the protocol -required post treatment follow- up period.
Gilead GLPS: Gilead GLPS
Email:  
or
Fax: 
7.4.2.2. Reporting Process for Gilead Concomitant Medications
Special situations that involve Gilead concomitant medications that are not considered stud y 
drug must be reported within 24 hours of the investigator’s knowledge of the event to Gilead 
GLPSutilizing the paper special situations report form to:
Gilead GLP S: Gilead GLPS
Email:  
or
Fax: 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Special situations involving non -Gilead concomitant medications do not need to be reported 
on the SSR form; however, special situations that result in AEs due to a non -Gilead 
concomitant medication, must be reported as an AE.
7.4.2.3. Pregnancy  Reporting Process
The invest igator should report pregnancies in females, and/or female partners of male 
participants that are identified after initiation of study  drug and throughout the study , 
including the protocol -required posttreatment follo
w-up period to be reported, to Gilead 
GLPSusing the pregnancy  report form within 24 hours of becoming aware of the pregnancy . 
Contact details for transmitting the pregnancy  report form are as follows:
Gilead GLPS: Gilead GLPS
Email:  
or
Fax: 
PPD
PPD
PPD
PPD
PPD
PPD
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 52 25 Septemeber 2020The pregnancy itself is not considered an AE, nor is an induced elective abortion to terminate 
a pregnancy  without medical reasons.
All other premature terminations of pregnancy  (eg, a spontaneous abortion, an induced 
therapeutic abortion due to complications or other medical reasons) must be reported within 
24hours as an SAE, as described in Section 7.4.1. The underl ying medical reason for this 
procedure should b
e recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described 
in Section 7.4.1. Furthermore, an y SAE occurring as an adverse pregnancy outcome post 
study  must be reported to the Gilead 
GLPS .
The participant should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome of the pregnancy /partner pregnancy  should be reported to Gilead 
GLPSusing the pregnancy  outcome report form. If the end of the pregnancy /partner 
pregnancy  occurs after the study  has been completed, the outcome should be reported 
directly  to Gilead GLPS . Gilead GLPS contact information is as follows: email: 
 and fax: . 
Refer to 
Appendix 2for Pregnancy  Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements.
7.5. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable FDA Code of 
Federal Regulations, the European Union Clinical Trials Directive (2001/20/EC) and relevant 
updates, and other country
-specific legislation or regulations, Gilead may  be required to expedite 
to worldwide regulatory  agencies reports of SAEs which may  be in the form of line -listings , 
serious adverse drug reactions, or SUSARs. I n accordance with the European Union Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide reg ulatory  
agencies and the relevant I EC in concerned m ember states of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the IBor relevant l ocal label as applicable. 
All investigators will receive a safet y letter notifying them of relevant suspected unexpected 
serious adverse reaction (SUSAR )reports associated with an y study  drug . The investigator 
should notify  the IRB of SUSAR reports as so on as is practical, where this is required b y local 
regulatory  agencies, and in accordance with the local institutional policy . 
PPD
PPD
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 53 25 Septemeber 20207.6. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnorma lities without clinical significance are not to be recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , urinaly sis) that require 
medical or surgical intervention or lead to study  drug interruption , modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, ECG, X -rays, vital signs) that are associated with 
signs and/or s ymptoms must be recorded as an AE or SAE if they  meet the definition of an AE 
(or SAE) as described in Sections 7.1.1 and7.1.2. If the laboratory  abnormality  is part of a 
syndrome, record the s yndrome or diagnosis ( eg,anemia) not the laboratory result (ie, decreased 
hemoglobin).
Severity  should be recorded a nd graded according to the CTCAE Toxicity Grading Scale, 
Version 5in Appendix 4. For AEs associated with laboratory  abnormalities, the event should be 
graded on the basis of the clinical severity  in the context of the underly ing conditions; this may  
or may not be in agreement with the gr ading of the laboratory  abnormality .
7.7. Toxicity Management 
All clinical and clinicall
y significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3, and as outlined below.
Grade 3 or 4 clinicall y significant labor atory  abnormalities should be confirmed by  repeat testing 
as soon as possible, and preferabl y within 3 calendar days after receipt of the original test results.
The Gilead 
medical monitor should be consulted prior to study  drug discontinuation when 
medical ly feasible.
7.7.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the investigator.
7.7.2. Grades 3 Laboratory Abnormality or Clinical Event
For a Grade 3 clinicall y significant laboratory  abnormality  or clinical event, thestudy  drug
may be continued if the event is considered to be unrelated to the study  drug .
For a Grade 3 clinicall y significant laboratory  abnormality  or clinical event confirmed by  
repeat testing, that is considered to be related to the study  drug , then the study  drug should be 
withheld until the toxicity returns to ≤Grade 2.
If a laboratory  abnormality  recurs to ≥ Grade 3 following rechallenge with the study  drug and 
is considered to be related to thestudy  drug , then the study  drug should be permanentl y 
discontinued and the participant managed according to local practice. Recurrence of 
laboratory  abnormalities considered unrelated to thestudy  drug may not require permanent 
discontinuation.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 54 25 Septemeber 20207.7.3. Grades 4 Laboratory Abnormality or Clinical Event
For a Gra de4 clinicall y significant laboratory  abnormality  or clinical event confirmed by  
repeat testing, that is considered to be related to the study  drug , the study  drug should be 
permanentl y discontinued and the participant managed according to local practice. The 
participant should be followed as clinicall y indicated until the laboratory abnormality returns 
to baseline or is otherwise explained, whichever occurs first. A clinically  significant Grade 4 
laboratory  abnormality  that is not confirmed by  repeat test ing should be managed according 
to the algorithm for the new toxicity  grade.
Study  drug may be continued without dose in
terruption for a clinicall y non significant 
Grade 4 laboratory  abnormality  (eg, Grade 4 CK elevation after strenuous exercise , 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to thestudy  drug .
Treatment -emergent toxicities will be noted by  the investigator and brought to the attention of 
the Gilead medical m onitor, and the appropriate course of action will be discussed and decided. 
Whether or not considered treatment related, all participants experiencing AEs must be 
monitored periodicall y until sy mptoms subside, any abnormal laboratory  values have resolved or 
returned to baseline levels or they  are considered irreversible, or until there is a satisfactory  
explanation for the changes observed.
Any questions regarding toxicity  management should be directed to the Gilead medical monitor .
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 55 25 Septemeber 20208. STATISTICAL  CONSIDERA TIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objectives of this study  are as follows:
To evaluate the effect of filgotinib on a mixed OATP/CYP3A, OATP/ BCRP, and OATP 
substrates using phenotypic probes
The secondary  objective sof this study  areas follows:
To evaluate the safet y and tolerability  of multiple filgotinib doses administered alone or in 
combination with probe drugs .
8.1.2. Primary Endpoint
The primary  endpoint of this study  isas follows:
PK parameters AUC last, AUC inf, and C maxof ATV, PRA , and ROS . 
8.1.3. Secondary Endpoint
The secondary  endpoints of this study  are as follows:
Incidences of AEs 
Laboratory  abnormalities
Vital signs
8.2.
Planned Analyses
8.2.1. Final Analysis
The final analy sis will be performed after all participants have completed the study , outstanding 
data queries have been resolved or adjudicated as unresolvable, and the data have been cleaned 
and finalized.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 56 25 Septemeber 20208.3. Analysis Conventions
8.3.1. Analysis Sets
8.3.1.1. All Randomized Analy sis Set
The All Randomized Analy sis Set includes all participants randomized into the study  after 
screening. This is the primary  anal ysis set for safety  listings.
8.3.1.2. Safety Anal ysis Set
The Safet y Analysis Set will include all randomized participants who received at least 1 dose of 
study  drug . Participants who received treatm ent other than that to which they  were assigned will 
be anal yzed according to the treatment received.
8.3.1.3. Pharmacokinetics Analy sis Set
The PK Anal ysis Set will include all 
randomized participants who received at least 1 dose of 
study  drug and had at least 1 n onmissing PK concentration datum reported by  PK laboratory for 
each respective anal yte
.
8.3.2. Data Handling Conventions
For summary  statistics, PK concentration values below the limit of quantitation will be treated as 
zero at predose and 1-half of the lower limit of quantitation (LLOQ) for postdose time points.
Laboratory  data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quantitation will be imputed to the value of the lower or upper limit minus or plus 
1signi ficant d
igit, respectively  (eg,if the result of a continuous laboratory  test is < 20, a value 
of19 will be assigned; if the result of a continuous laboratory  test is < 20.0, a value of 19.9 will 
be assigned).
Missing data can have an impact upon the interpretati on of the study data. As this study  is of 
short duration, it is anticipated that missing data will be minimal. I n general, values for missing 
data will not be imputed. However, a missing pretreatment laboratory  resul t would be treated as 
normal (i e,no tox icity grade) for the laboratory  abnormality  summary .
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized and descriptive statistics will be 
provided. 
Demographic summaries will include sex, race/ethnicity , and age.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 57 25 Septemeber 20208.5. Safety Analysis
All safet y data collected on or after the date that study drug was first administered up to 30days
after last study drug administration will be summarized by  treatment ( according to the study drug 
received) using the S afety  Analysis Set. 
8.5.1. Extent of Exposure
A participant ’s extent of exposure to study  drug data will be generated from the study  drug
administration data. Exposure data will be listed.
8.5.2. Adverse Events
Clinical and laboratory  AEs will be coded using the current versi on of t he Medical Dictionary  
for Regulatory  Activities (MedDRA). S ystem 
organ class(SOC) , high-level group term, 
high- l evel term, preferred term (PT), and l ower -level term will be attached to the clinical 
database.
Treatment -emergent AE s(TEAEs ), serious TEAE s, and TEAE sleading to discontinuation of 
treatment will be summarized by  treatment, SOC , and PT using the current version of MedDRA. 
Adverse event data will be listed by  participant .
8.5.3. Laboratory Evaluations
Laboratory  results and change sfrom predose values for selected lab oratory tests will be 
summarized by  treatment sequence at scheduled visits. The incidence of treatment-emergent 
graded laboratory  abnormalities will be summarized by  treatment. Listings of individual 
participant laboratory  results wi ll be provided.
8.5.4.
Other Safety Evaluations
Vital signs and ECG data will be summarized by  treatment /treatment sequence ..
8.6.
Pharmacokinetic Analysis
An anal ysis of variance (ANOVA) using a mixed -effects model with treatment, period, and 
sequence as fixed effect s and participant as a random effect will be fitted to the natural 
logarithmic transformation of PK parameters (AUC last, AUC inf, Cmax)for each anal yte. 
Two-sided 90% CIs will be calculated for the ratios of geometric least -squares means (GL SMs) 
of primary  PK parameters between test (Treatment B) versus reference (Treatment A) 
treatments. 
Lack of PKinteraction between the test and reference treatments will be concluded if the 
90% CIs for the GLSM ratios are contained within the 0.70 and 1.43 ra nge for ATV, PRA, and 
ROS AUC and Cmax. Additional analyses may  be performed if useful and appropriate.
Plasma concentrations and PK parameters AUC last, AUC inf, Cmax, %AUC exp, Clast, Tmax, Tlast, t1/2, 
CL/Z, λzand V z/Fwill be listed and summarized for 
ATV, PRA ,and ROS using descriptive 
statistics by  treatment. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 58 25 Septemeber 20208.7. Sample Size
With 26 evaluable participants ,the estimated two -sided 90% CI  of the GLSM ratio of test versu s 
reference treatments, with regards to AUC inf, AUC last,and C max, will be within [70%, 143%] with 
≥ 85% probability , if the true GL SM ratio is 1.0. This is assuming a standard deviation (SD) of 
differences of no more than 0.569 on a natural logarithm scale, supported by PK data from Study  
GS-US-402-2102. With 4 participants for overage, a to tal sample size of 30 participants will be 
required.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 59 25 Septemeber 20209. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with International Council 
for Harmonisation (of Technical Re quirements for Pharmaceuticals for Human Use) ( ICH)
E6(R2) GCP and applicable laws and regulations.
9.1.2. Financial Disclosure
The investigator and subinvestigators will provid edocumentation of their financial interest or 
arrangements with Gilead or proprietary  interests in the study drug under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study . The i nvestigator and subinvestigator agree to notify  Gilead of any  
change in reportable interests during the study  and for 1 year following completion of the study. 
Study  completion is defined as the date when the last participant completes the protocol- defined 
activities.
9.1.3. Institutional Review Board Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, ICF, and any  accompan ying material to be provided to the participant (such as 
advertisements, participant information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB. The 
investigator will not begin an y stud y participant activities until 
approval from the IRBhasbeen documented and provided as a letter to the investigator and 
documentation of the approval is provided to the investigator .
Before implementation, the investigator will submit to and receive documented approval from 
the IRBfor any modifications made to the protocol or any accompan ying material to b e provided 
to the participant after initial IRBapproval, with the exception of those necessary  to reduce 
immediate risk to study  participants.
9.1.4. Informed Consent
The i
nvestigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  before undertaking any  study -related procedures. The investigator 
must use the most current I RB-approved ICFfor documenting written in formed consent. Each 
ICFwill be appropriatel y signed and dated b y the participant, the person conducting the consent 
discussion, and also by  an impartial witness if required by IRB or local requirements. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 60 25 Septemeber 2020The ICFwill inform participants about genomic testing and/or planned sample 
retention Confidentiality
The investigator must en sure that participants’ anony mity will be strictly  maintained and that 
their identities are protected from unauthorized parties. Only  an identification code and any  other 
unique identifier (s) as allowed by  local law (such as y ear of birth) will be recorded on an y form 
or biological sample submitted to the s ponsor, IRB,or the laboratory . Laboratory  specimens 
must be labeled in such away as to protect participant identity  while a llowing the results to be 
recorded to the proper participant . Refer to specific laboratory  instructions. NOTE: The 
investigator must keep a screening log showing codes, names, and addresses for all participants 
screened and for all participants enrolled in the study . Participant data will be processed in 
accordance with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
IB, this protocol, eCRF, study  drug information , and any  other study  information, remain the 
sole and exclusive property  of Gilead during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of t he study
 or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following 2categories: (1) investigator’s study file and 
(2)participant clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF, IRB governmental 
approval with correspondence, ICF, drug records, s taff curriculum vitae and authorization forms, 
and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each participant :
Participant identification (name , date of birth, gender)
Documentation that participant meets eligibility  criteria, ie,history , phy sical examination, 
and confirmation of diagnosis (to support inclusion and exclusion criteria)
Documentation of the reason(s) a consented participant is not enrolled
Participation in study  (including study  number)
Study  discussed and date of informed consent
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 61 25 Septemeber 2020Dates of all visits
Documentation that protocol- specific procedures were performed
Results of efficacy  parameters, as required b y the protocol
Start and end date s(including dose regimen) of study  drug , including dates of dispensing and 
return
Record of all AEs and other safety  parameters (start and end date ;causality  and severit y), 
and documentation that adequate medical care has been provided for an y AE
Concomitant medication (including start and end dates , dose if relevant , and dose changes)
Date of stud y completion and reason for earl y discontinuation, if it occurs
All clinical study  documents must be retained b y the investigator for at least 2 years or according 
to local laws, whichever is longer, after the last approval of a marketing application in an I CH 
region (ie, US, Europe, or Japan) and until there are no pending or planned marketing 
applications in an I CH region; or, if no application is file d or if the application is not approved 
for such indication, for 2years after the investigation is discontinued and regulatory  authorities 
have been notified. Investigators may  be required to retain documents longer if specified by  
regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The investigator 
must notify  Gilead before destroy ing an y clinical study records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the i nvestigator and Gilead to store 
these records securel y awa y from t he site so that they  can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
participant , appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
Foreach participant enrolled , an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. The eCRF should 
be completed on the day  of the participant visit to enable the sponsor t o perform central 
monitoring of safet y data , whenever possible. The Eligibility  Criteria eCRF should be completed 
only after all data related to eligibility  have been received and the participant has been enrolled. 
Subsequent to data entry , a study  monitor will perform source data verification SDV within the 
EDC system. Original entries as well as an y changes to data fields will be stored in the audit trail 
of the sy stem. Prior to database lock (or any  interim time points as described in the clinical data 
management plan), the investigator will use his/her login credentials to confirm that the forms 
have been reviewed, and that the entries accurately reflect the information in the source 
documents. The eCRF capture sthe data required per the protocol schedule of events and 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 62 25 Septemeber 2020procedures. System -generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  the monitor or internal Gilead staff who routinely  review the 
data for completeness, correctness, and consistency. The site coordinator is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason f
or the update (eg ,data entry  
error). At the conclusion of the study , Gilead will provide the site with a read -only archive copy  
of the data entered b y that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Investigator 
Inspections
The investigator will make available all source documents and other records for this study to 
Gilead’s appointed study monitor s, to IRB, or to regulatory  authorit y or health authority 
inspectors.
9.1.8. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. S ponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  participants, 
may be made onl y by Gilead. The 
investigator must submit all protocol modifications to IRBin 
accordance with local requirements and receive documented IRB approval before modifications 
may be implemented.
9.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency . Gilead will ensure 
that the re port meets the standards set out in the ICH Guideline for Structure and Content of 
Clinical Study  Reports (ICH E3). Note that an abbreviated report may  be prepared in certain 
cases. 
Investigators in this study  may  communicate, orally  present, or publish i n scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least 2 years .
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation. 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 63 25 Septemeber 2020No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.5).
The investi gator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent 
protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol (eg,attendance at investigator's m eetings ). If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to federal and state agencies any  
expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reim bursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the medical monitor must have direct access to 
the investigator’s source documentation in order to verify  the accuracy  of the data recorded in 
the eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to any  participant records needed to 
verify  the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through any  type of monitoring (central, onsite) are resolv ed.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or Gilead may  conduct inspections or audits of the 
clinical study . If the 
investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The i nvestigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Disconti nuation
Both Gilead and the investigator reserve the right to terminate the study  at any  time. Should this 
be necessary , both parties will arrange discontinuation procedures and notify  the particpants , 
appropriate regulatory  authority ,andIRBs. In termina ting the study , Gilead and the i nvestigator 
will ensure that adequate consideration is given to the protection of the participants’ interests.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 64 25 Septemeber 202010. REFERENCES
Chu X, L iao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical Probes and Endogen ous 
Biomarkers as Substrates for Transporter Drug -Drug Interaction Evaluation: 
Perspectives From the International Transporter Consortium. Clin Pharmacol 
Ther 2018;104 (5):836 -64.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Elsby  R, Hilgendorf C, Fenner K. Understanding the critical disposition pathway s of statins to 
assess drug -drug interaction risk during drug development: it's not just about 
OATP1B1. Clin Pharmacol Ther 2012;92 (5):584 -98.
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane 
transporters in drug development. Nat Rev Drug Discov 2010;9 (3):215 -36.
Huang SM, Woodcock J. Transporters in drug development: advancing on the Critical Path. Nat 
Rev Drug Discov 2010;9 (3):175
-6.
Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Ry chlewska -Hanczewska A, Dudek A, et 
al. Efficacy  and Safety of Filgotinib, a Selective Januse Kinase 1 Inhibitor, in 
Patients with Active Psoriatic Arthritis (EQUATOR): Results f rom a 
Randomized, Placebo-Controlled Phase 2 Trial. Lancet 2018;392:2367-77.
Meyer zu Schwabedissen HE, Kim RB. Hepatic OATP1B transporters and nuclear receptors 
PXR and CAR: interplay, regulation of drug disposition genes, and single 
nucleotide poly morphi sms. Mol Pharm 2009;6 (6):1644 -61.
Neuvonen PJ. Drug interactions with HMG -CoA reductase inhibitors (statins): the importance of 
CYP enzy mes, transporters and pharmacogenetics. Curr Opin Investig Drugs 
2010;11 (3):323 -32.
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 
polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin 
Pharmacol Ther 2007;82 (6):726 -33.
van der Heijde D, Baraliakos X, Gensler L S, Maksy mowy ch WP, Tseluy ko V, Nadashkevich O, 
et al. Efficac y and Safet y of Filgotinib, a Selective Janus Kinase 1 I nhibitor, in 
Patients with Active Ankylosing Spondy litis (TORTUGA): Results from a 
Randomized Placebo-Controlled, Phase 2 Trial. Lancet 2018;392:2378 87.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 65 25 Septemeber 202011. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. Common Terminology Criterial for Adverse Events (CTCAE) Gradi ng Scale v5.0
Filgotinib  
Protocol GS-US-417-5937 Final 
Gilead Sciences, Inc.  Original 
CONFIDENTIAL Page 66  25 Septemeber 2020 Appendix 1. Investigator Signature Page 
 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
USA 
 
STUDY ACKNOWLEDGEMENT 
 
A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between 
Filgotinib and Stains as Probe Drugs in Healthy Participants 
Original Protocol, 25 Septemeber 2020  
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
 
Name (Printed) 
Responsible Person’s Title  Signature 
 
   
Date   
INVESTIGATOR STATEMENT 
 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they are fully informed about the drugs and the study. 
   
Principal Investi
gator Name (Printed)  Si gnature 
 
   
Date  Site Numbe r 
 25 September 2020
PPD
PPD
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 67 25 Septemeber 2020Appendix 2. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of 
Childbearing Potential
For the purposes of this study , a female born participant is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming postmenopausal unless the 
participant is permanently  sterile or hasmedical ly documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are ≥ 54 years of age with 
cessation of previously  occurring menses for ≥ 12 months without an alternative cause. In 
addition, women < 54 years of age with amenorrhea of ≥ 12 months may  also be considered 
postmenopausal if their follicle -stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization inc ludes h ysterectomy , bilateral oophorectom y, or bilateral 
salpingectomy in a female participant of any  age.
b.Definition of Male Fertility
For the purposes of this study , a male born participant is considered fertile after the initiation of 
puberty  unless the participant is permanentl y sterile by bilateral orchidectomy  or medical 
documentation.
2)Contraception Requirements for Female Participants
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Filgotinib is contraindicated in pregnancy as a malf ormative effect has been 
demonstrated/suspected or is unknown taking into consideration class effect and/or strong 
suspicion of human teratogenicity /fetotoxicity  in earl y pregnancy based on nonclinical data. Data 
from clinical PK interaction studies of filgotinib have demonstrated that there is no reduction in 
the clinical efficacy  of hormonal contraception. Refer to the latest version of the IB for additional 
information.
b.Contraception Requirements for Female Participants of Childbearing Potential
The inclusion of female participants of childbearing potential requires the use of highl y effective 
contraceptive measures with a failure rate of < 1% per y ear. They  must have a negative serum 
pregnancy  test at screening and admission and a urine negative pregnancy  test at the Admission 
(Day  1) prior to randomization .Pregnancy tests will be performed as specified in the protocol .
Female participants of childbearing potential must agree to use one of the contraceptive methods 
below from Screening until 
1 weekafter the last dose of study  drug.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 68 25 Septemeber 2020Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the participant ’s preferred and usual 
lifesty le. 
Or
Consistent and corr ect use of 1 of the following methods of birth control listed below: 
Hormonal or non -hormonal intrauterine device (IUD) 
Subdermal contraceptive implant
Bilateral tubal occlusion (upon medical assessment of surgical success)
Vasectom y in the male partner (upon medical assessment of surgical success)
Or 
Female participants who wish to use a hormonally -based method must use it in conjunction with 
a barrier method, preferably  a male condom. Hormonal methods are restricted to those associated 
with the inhibit ion of ovulation. Hormonally- based contraceptives and barrier methods permitted 
for use in this protocol are as follows:
Hormonal methods (each method must be used with a barrier method, preferably  male 
condom)
Oral contraceptives (either combined or proge sterone only )
Injectable progesterone
Transdermal contraceptive patch
Contraceptive vaginal ring
Barrier methods (each method must be used with a hormonal method)
Male condom (with or without spermicide)
Female condom (with or without spermicide)
Diaphragm with spermicide
Cervical cap with spermicide
Sponge with spermicide
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 69 25 Septemeber 2020Inclusion of methods of contraception in this list of permitted methods does not imply  that the 
method is approved in any  country  or region. Methods should only  be used if locally  approved. 
Female participants must also refrain from egg donation and in vi tro fertilization during 
treatment and until the end of the contraceptive requirement.
3)Contraception Requirements for Male 
Participants
It is theoreticall y possible that a relevant s ystemic concentration of study  drug may  be achieved 
in a female partner from exposure of the male participant ’s seminal fluid and poses a potential 
risk to an embry o/fetus. Therefore, male participants with female partners of childbearing 
potential must use condoms during treatment until 1 week after last dose of study  drug. 
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea me thod. A female condom and a male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Female participants will be instructed to notify  the investigator if they  become pregnant or 
suspect they are pregnant at any  time f rom start of the study  to1 week after the last dose of study  
drug.
Male subjects whose partner has become pregnant or suspects she is pregnant from start of study  
through one week after last dose of study  drug must also report the information to the 
inves tigator.
Study  drug must be discontinued immediately  upon discussion with the medical monitor .
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section 7.4.2.3.
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 70 25 Septemeber 2020Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1 Grade 2 Grade 3 
Continue study drug dosing at the 
discretion of the investigator Repeat lab to confirm toxicity 
grade 
If confirmed , and possibly or probably related to study drug( s): If confirmed and 
unrelated to study 
drug( s), dosing may 
continue at the 
discretion of the 
investigator. 1. Withhold study drug( s) until !s Grade 2 
2. Restart all study drug( s) at full dose upon discussion with the 
Gilead Medi cal Monitor 
If Grade 3 or 4 recurrence is 
confirmed and possibly or 
probably related to study drug( s), 
discontinue all study drug (s) 
permanentl y, and manage the 
subject according to local practice . If Grade 3 or 4 recurrence is 
confirmed and unrelated to 
study drug( s), continue all 
investigational medicinal 
product( s) at the same dose at 
the discretion of the 
investigator . Grade 4 
If confirmed , and 
possibly or probably 
related to study 
drug( s), discontinue 
study( s) dosing 
permanently , and 
manage subject 
according to local 
practice. Subject 
should be followed as 
clinically indicated 
until the laboratory 
abnormality return s to 
baseline , or is 
otherwi se ex plained . 
Filgotinib
Protocol GS -US-417-5937 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 71 25 Septemeber 2020Appendix 4. Common Ter minology Criterial for Adverse Events (CTCAE)
Grading Scale v5.0
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50